1	Human SARS-CoV-2 challenge resolves local and systemic response dynamics
2	
3 4 5 7 8 9	Rik G.H. Lindeboom ^{*1,3} , Kaylee B. Worlock ^{*2} , Lisa M. Dratva ¹ , Masahiro Yoshida ² , David Scobie ⁶ , Helen R. Wagstaffe ⁴ , Laura Richardson ¹ , Anna Wilbrey-Clark ¹ , Josephine L. Barnes ² , Krzysztof Polanski ¹ , Jessica Allen-Hyttinen ² , Puja Mehta ² , Dinithi Sumanaweera ¹ , Jacqueline Boccacino ¹ , Waradon Sungnak ¹ , Ni Huang ¹ , Lira Mamanova ¹ , Rakesh Kapuge ¹ , Liam Bolt ¹ , Elena Prigmore ¹ , Ben Killingley ⁶ , Mariya Kalinova ⁵ , Maria Mayer ⁵ , Alison Boyers ⁵ , Alex Mann ⁵ , Vitor Teixeira ² , Sam M. Janes ² , Rachel C. Chambers ² , Muzlifah Haniffa ¹ , Andrew Catchpole ⁵ , Robert Heyderman ⁶ , Mahdad Noursadeghi ⁶ , Benny Chain ⁶ , Andreas Mayer ⁶ , Kerstin B. Meyer ¹ , Christopher Chiu ⁴ , Marko Z. Nikolić ^{†2} , Sarah A. Teichmann ^{†1}
11	
12	1. Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, CB10 1SA, UK
13	2. UCL Respiratory, Division of Medicine, University College London, London, WC1E 6JF UK
14	3. The Netherlands Cancer Institute, Amsterdam, the Netherlands
15	4. Department of Infectious Disease, Imperial College London, London
16	5. hVIVO, London, UK
17 18 19	6. Research Department of Infection, Division of Infection and Immunity, University College London, London, UK.
20	*co-first authors
21	†co-senior authors
22	
23 24 25	Correspondence to: Rik G.H. Lindeboom (<u>r.lindeboom@nki.nl</u>), Marko Z. Nikolić (<u>m.nikolic@ucl.ac.uk</u>), Sarah A. Teichmann (<u>st9@sanger.ac.uk</u>)
26	
27	Abstract
28 29 30	The COVID-19 pandemic is an ongoing global health threat, yet our understanding of the cellular disease dynamics remains limited. In our unique COVID-19 human challenge study we used single cell genomics of nasopharyngeal swabs and blood to temporally resolve abortive, transient and sustained
31	inetetitiesprinrint cepseroneugations individual beechatliengedeeviewiewieweenstud an Resectivalie Cinical mattises

32 revealed rapid changes in cell type proportions and dozens of highly dynamic cellular response states 33 in epithelial and immune cells associated with specific timepoints or infection status. We observed that 34 the interferon response in blood precedes the nasopharynx, and that nasopharyngeal immune infiltration 35 occurred early in transient but later in sustained infection, and thus correlated with preventing sustained 36 infection. Ciliated cells showed an acute response phase, upregulated MHC class II while infected, and 37 were most permissive for viral replication, whilst nasal T cells and macrophages were infected non-38 productively. We resolve 54 T cell states, including acutely activated T cells that clonally expanded 39 while carrying convergent SARS-CoV-2 motifs. Our novel computational pipeline (Cell2TCR) 40 identifies activated antigen-responding clonotype groups and motifs in any dataset. Together, we show 41 that our detailed time series data (covid19cellatlas.org) can serve as a "Rosetta stone" for the epithelial 42 and immune cell responses, and reveals early dynamic responses associated with protection from 43 infection.

- 44
- 45

46 Main

47 Coronavirus Disease 2019 (COVID-19) is a potentially fatal disease caused by the severe acute 48 respiratory syndrome coronavirus 2 (SARS-CoV-2), which gave rise to one of the most severe global 49 public health emergencies in recent history. Studies by us and others have uncovered that perturbed 50 antiviral and immune responses to SARS-CoV-2 underlie severe and fatal outcomes, where for example impaired type I interferon responses^{1,2}, decreases of circulating T cell and monocyte subsets^{3–5}, and 51 52 increased clonal expansion of T and B cells⁴ are associated with a more severe outcome. However, 53 accurate detection and interpretation of the immune response during COVD-19 has been hampered by 54 heterogeneous responses caused by numerous non-host factors that affect immune and clinical 55 outcomes that are frequently unmeasurable and uncontrolled. These include infection characteristics 56 such as viral dose, strain and time since exposure, together with clinical features including 57 comorbidities, standard of care and pre-existing immunity. In particular, the observed immune response 58 may represent different phases, from early viral detection to later adaptive responses, depending on the 59 time between infection and sampling.

60

Since the exact time at which patients were exposed to SARS-CoV-2 is nearly always unknown, it can be challenging to accurately delineate severity-associated and temporal effects such as early interferon signaling and late adaptive immune responses¹⁻⁶. Determining the dynamics of SARS-CoV-2 infection and the body's response is therefore crucial to understand how the immune response is orchestrated and how risk factors can impact this. In addition, while many studies have investigated responses to COVID-19 during the course of the disease^{7,8}, it has thus far not been possible to study the early phases of

67 exposure and the infection event itself in humans. In particular, studies of natural infection are unable 68 to capture events in those who are exposed to the virus but do not develop sustained viral infection, 69 which might be critical in preventing dissemination and disease. Furthermore, the activation and 70 expansion of antigen-responding T cells (versus bystanders) has been difficult to pinpoint in previous 71 "snapshot" datasets^{4,5}. Here, we trace their development and integrate the paired TCR chains for the 72 first time.

73

74 Human SARS-CoV-2 challenge model

75 To resolve epithelial and immune cell responses over time from SARS-CoV-2 exposure, we conducted 76 a first of its kind, human COVID-19 challenge study⁶. In this model, young adults seronegative for 77 SARS-CoV-2 spike were inoculated intranasally with a wild-type pre-Alpha SARS-CoV-2 virus strain 78 (SARS-CoV-2/human/GBR/484861/2020) in a controlled environment⁶. Prior to challenge, volunteers 79 underwent extensive screening to exclude risk factors for severe disease and eliminate confounding 80 effects of comorbidities. As risk mitigation and to maximize physiological relevance, participants were 81 inoculated with the lowest culture-quantifiable inoculum dose of 10 Tissue Culture Infectious Dose 50 82 (TCID_{50}) . There were no serious adverse events and symptoms resolved spontaneously without 83 treatment.

84

We studied local and systemic immune responses at single cell resolution in 16 participants. The highly controlled nature of this experimental model allowed baseline measurements on the day before inoculation, followed by detailed time series analyses of cellular responses after inoculation and subsequent infection, both systemically and in the nasopharynx, to decipher antiviral responses against SARS-CoV-2 in a precise time-resolved manner.

90

91 Following inoculation, 6 participants from the cohort developed a sustained infection as defined by at 92 least 2 consecutive quantifiable viral load detections by PCR, along with symptoms (Fig. 1a and 93 Extended Data Fig. 1). In contrast, three individuals produced multiple sporadic and borderline-94 positive PCR tests between day 1.5 and 7 post-inoculation. While these participants remained symptom 95 free and did not meet the earlier established criteria to be classified as "sustained infection", we assigned 96 them to a separate group of "transient infection" to investigate factors associated with this unique 97 phenotype.




Figure 1: Extensive temporal cell state dynamics after SARS-CoV-2 inoculation.

(a) Illustration of study design and cohort composition. (b-c) UMAPs of all nasopharyngeal cells, color-coded by their broad cell type annotation in (b), by the infection group in the top panel of (c), and by days since inoculation in the bottom panel of (c). Only cells from sustained infection cases are shown in the bottom panel of (c). (d-e) UMAPs as in (b-c), but showing all PBMCs. (f) Fold changes in abundance of nasopharynx resident broad immune cell type categories. Immune cell abundances were scaled to the total amount of detected epithelial cells in every sample prior to calculating the fold changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances.

98

99

Seven participants remained PCR negative throughout the quarantine period, indicating that these individuals successfully prevented the onset of a sustained or transient infection. Due to the fact that these participants all remained seronegative, but were observed to display early innate immune responses (see below), we termed these abortive infections (as opposed to uninfected due to for example antibody-mediated sterilizing immunity).

105

106 Broad cellular transitions observed over time and infection groups

To comprehensively identify and time responses to SARS-CoV-2 exposure in these phenotypicallydivergent groups, we performed single cell RNA sequencing (scRNAseq) and single cell TCR- and
BCR-seq at up to seven time points (Fig. 1a). In addition, we complemented the RNA measurements
in PBMCs with CITE-seq measurements to quantify 123 surface proteins to aid cell type annotation. At

each time point, we collected PBMCs and nasopharyngeal swabs to study both the systemic immune

response and the epithelial and local immune response at the site of inoculation, respectively. Of note, 112 113 while most PBMC and nasopharyngeal time points were matched, we included more early 114 nasopharyngeal and later PBMC time points as we anticipated more immediate local responses. In total, 115 we generated over 600K single cell transcriptomes across 181 samples, which include 371,892 PBMCs 116 and 234,182 nasopharyngeal cells. We used predictive models and marker gene expression to annotate 117 202 cell states in total (see *Methods*; Extended Data Fig. 2-5), including multiple newly identified cell 118 states that will be discussed throughout this manuscript. Importantly, both datasets contained all 119 expected cell types (Fig. 1b,d; Extended Data Fig. 2a-b), including clearly resolved epithelial and 120 immune compartments in the nasopharyngeal samples, which enabled us to study both the local and 121 systemic immune response. Strikingly, even when visualizing all cells at once in Fig. 1b.d, the 122 "infection group" and "days since inoculation" mark specific groups of cells (Fig. 1c,e), indicating that 123 there are large changes in cell fate over time and infection groups across the different cell type 124 compartments.

125

126 Innate and adaptive immune infiltration to site of inoculation

127 We first investigated how the immune landscape is affected by viral inoculation and subsequent 128 infection. We used generalized linear mixed models (GLMM) to quantify the changes in cell type 129 abundances over time since inoculation compared to the day prior to inoculation (-1). This allowed us 130 to perform paired longitudinal modeling of donor-specific effects while accounting for technical and biological variation using random effect terms. Analysis of the nasopharyngeal resident immune 131 132 compartment revealed that all immune cell types significantly infiltrate the site of inoculation after 133 exposure to SARS-CoV-2 (Fig. 1f). Strikingly, the timing of infiltration strongly differed between 134 participants with a sustained, transient or abortive infection. During sustained infections, immune 135 infiltration started at day 5 after inoculation and continued to increase until day 10. In stark contrast, 136 transient infections led to immediate and robust immune infiltration, followed by a decrease and smaller 137 secondary infiltration event at day 10. Last, abortive infections do not lead to any obvious patterns of 138 immune infiltration.

139

Interestingly, both sustained and transient infections lead to infiltration of innate and adaptive immune cells. However, the increase of innate immune cells such as plasmacytoid dendritic (pDC), natural killer (NK), gamma/delta T (g/d T), and mucosal-associated invariant T (MAIT) cells was quicker and of greater magnitude than infiltration by adaptive immune cells in sustained infections. In line with this, in transient infections, the increase of immune cells at day 1 was also greatest in the innate immune compartment. The observed difference in timing of immune infiltration between transient and sustained

- 146 infections suggests that immediate immune recruitment and responses are associated with containing
- 147 SARS-CoV-2 infection and preventing the onset of a sustained infection and COVID-19.
- 148

149 Widespread systemic interferon response precedes response at site of inoculation

150 We next attempted to detect antiviral gene expression programs in any of the tissue resident and 151 circulating cells during infection. Gene expression analysis revealed that the interferon response genes 152 made up the dominant infection-induced gene expression module in participants with sustained 153 infection (Fig. 2a). Strikingly, interferon signaling was strongly activated in every cell type of both the 154 blood and in the nasopharynx, where up to 100% of some cell types at a given time took on a distinct 155 interferon stimulated cell state (Extended Data Fig. 6a, annotated in Extended Data Fig. 2-4 as IFN 156 stim), underscoring its widespread and dominant effect. Activation of interferon signaling was absent in abortive infection and only short-lived in transient infections (Extended Data Fig. 6a). Interestingly, 157 at the site of inoculation, we only detected widespread interferon activation from five days post-158 159 inoculation, whereas the interferon response in the blood peaks at day 3 post-inoculation and appears 160 to be stronger. This is unexpected, as we assumed that the cells that reside in the inoculated tissue should 161 be the first to respond through direct exposure to the virus and infected cells. Instead, it appears that the 162 immediate response to SARS-CoV-2 infection includes informing circulating immune cells before 163 tissue-resident cells through interferon signaling.




Figure 2: Cell-state-specific antiviral responses and infection

(a) Dotplot visualizing the mean expression of interferon stimulated genes across cell types and time since inoculation in participants with sustained infections, for nasopharyngeal cells (left plot) and PBMCs (right plot). (b) Dotplot as in (Fig 1f), showing myeloid cell types in sustained infection cases that significantly change at least one time point compared to pre-infection. Nasopharyngeal cells and PBMCs are shown in the left and right plot, respectively. (c) Boxplot showing the relative amounts of circulating inflammatory monocytes over time since inoculation in each infection group. (d) Boxplot showing the fraction of circulating MAIT cells that are activated over time since inoculation in each infection group. (e) Stacked barplot showing the amount of nasopharyngeal cells with at least one SARS-CoV-2 RNA read detected (after background subtraction), split by days since inoculation and color-coded by cell type. (f) Barplots showing the distribution of detected viral reads over the SARS-CoV-2 genome in the five most highly infected cell types. The blue line represents a loess fit over the data. The top-right inset illustration is shown to aid the interpretation of a uniform read distribution versus a 3' biased read distribution. (g) Boxplot showing the fraction of ciliated cells that are annotated into detailed response or infection cell states. Only cells from sustained infection cases are shown and split by days since inoculation. The Y axis for interferon (IFN) and acute-phase response (APR) positive ciliated cells is shown on the left, while the Y axis for infected ciliated cells is shown on the right. (h) Boxplot of the amount of viral sequencing reads per cell type. (i) Heatmap of spearman correlations between host gene expression and the amount of viral reads found in each cell, split by cell type. Shown genes correlate the highest with gene expression in ciliated cells. In all box plots, the central line and the notch are the median and its approximate 95% confidence interval, the box shows the interquartile range and the whiskers are extreme values upon removing outliers.

165

166

167 Temporal reduction of myeloid subsets immediately after viral exposure

168 To investigate the potential role of professional antigen presenting cells in the early immune response 169 to SARS-CoV-2, we next focused on changes in the nasopharyngeal resident and circulating myeloid 170 compartments during sustained infection. In contrast to most tissue-resident immune cells, myeloid 171 subsets largely decreased in frequency at the site of inoculation by day 3 after inoculation (Fig. 2b). In 172 particular, monocytes and activated DCs (also often referred to as migratory DCs, mature DCs or DC-173 LAMPs) were significantly reduced at the site of inoculation at day 3, consistent with the known role 174 of activated DCs in trafficking viral antigens to lymph nodes for presentation. After day 3, the number 175 of DCs at the site of inoculation increased above baseline, along with the global immune infiltration 176 associated with peak viral load in sustained infections. We also observed a decrease of circulating 177 myeloid cells during infection across all subsets at day 7, consistent with continued migration of these 178 cells into inflamed or lymphoid tissues at that time point. However, already at day 3 post-inoculation 179 there are strong decreases in some circulating myeloid subsets, where inflammatory monocytes (IL1B, 180 *IL6 & CXCL3* high) and cDC3s (monocyte-like dendritic cells) appear to migrate out of the circulation.

181

Strikingly, while all of the above mentioned responses were only observed in sustained infections, the
significant decrease in inflammatory monocytes was also observed in transient and abortive infections
(Fig. 2c and Extended Data Fig. 7a). This suggests that circulating inflammatory monocytes are able

to immediately respond to SARS-CoV-2 exposure, even if the viral infection is rapidly terminated,
 implying that exposure alone in the absence of virologically-confirmed infection with SARS-CoV-2

- 187 can result in a detectable (but restricted) immune response.
- 188

189 Novel MAIT subset is activated in both sustained and abortive infections

190 We next asked if such a detectable immune response across all infection groups could also be observed 191 in other cell types. When annotating unconventional T cells, we noted that MAIT cells could be further 192 divided into two subgroups, i.e. classical MAIT cells and activated MAIT cells with higher expression 193 of cytotoxicity and activation markers such as *PRF1* and *CD27* (Extended Data Fig. 6b). These 194 markers have previously been shown to be indicative of TCR-independent activation⁹. At day 3 post-195 inoculation, we observed near complete activation of the entire MAIT cell population in the blood in 196 sustained infections (Fig. 2d). Strikingly, the activation of MAIT cells was also present in abortive and 197 transient infections, which suggests that MAIT cells may rapidly sense exposure to a virus. Thus both 198 MAIT cells and inflammatory monocytes might play a key role in the immediate response to SARS-199 CoV-2. This further supports the notion that viral exposure, that does not lead to a sustained infection 200 and subsequent COVID-19, can still induce a detectable, yet restricted immune response.

201

202 Infection in epithelial and immune cells peaks a week after exposure and is most active in

203 ciliated cells

204 To study how the observed immune responses relate to viral infection dynamics, we included the SARS-205 CoV-2 ssRNA genome and its transcripts in our analyses. This allowed us to quantify virions and viral 206 gene expression alongside transcriptome dynamics of infected host cells. As expected, infected cells 207 were almost exclusively found in the nasopharynx of participants with sustained infections (2505 out 208 of 2512 cells with viral RNA). We detected infection of multiple cell types at day 5 post-inoculation, 209 which peaked at day 7 (Fig. 2e), followed by a rapid decrease at day 10 - 14 post-inoculation, showing 210 the narrow time window over which SARS-CoV-2 virion production occurred. These changes over time 211 were in line with qPCR results (Extended Data Fig 1b,c and Extended Data Table 1a,b), albeit with 212 the latter being more sensitive. Interestingly, we observed viral reads in both immune and epithelial 213 cells in the nasopharynx (Fig. 2e). In contrast to previous studies, we detected large numbers of SARS-214 CoV-2-containing CD8+ T cells, possibly due to the model being able to capture the narrow time 215 window in which these infected cells are highly abundant. Our results therefore show that, in addition 216 to epithelial cells, viral transcripts are also detectable at high levels in tissue-resident CD8+ T cells.

217

218 Non-productive SARS-CoV-2 infection of immune cells

219 Having identified infected cells, we next asked if these represented productive infections. Because 220 SARS-CoV-2 has a polyadenylated ssRNA genome, we were able to detect both viral transcripts and 221 genomes, which allowed us to separate non-productive and productive infections. In non-productive 222 infections only viral genomes would be present, leading to a fairly uniform distribution of detected viral 223 RNAs over the length of the viral genome (slightly 5' biased due to 5' tag sequencing). In contrast, a 224 productive infection requires viral transcription which is known to be highly biased towards the 3' end of the viral genome¹⁰. We observed that the viral RNA found in infected ciliated and goblet cells mainly 225 226 originated from the 3' end where most genes are encoded, while viral RNA was uniformly distributed 227 across the genome in infected CD8+T cells and macrophages (Fig. 2f). This suggests that immune cells 228 are not permissive for or are capable of preventing viral transcription and subsequent replication after 229 entry into the immune cell, while goblet and ciliated cells are susceptible to proliferative viral infection. 230 While the detection of inactive SARS-CoV-2 in macrophages could be a consequence of the engulfment 231 of virions and infected cells, it is unclear how infection of tissue-resident CD8+ T cells is achieved and

how this affects their function.

233

234 Hyper-infected ciliated cells are the main source of SARS-CoV-2 and produce anti-

235 inflammatory molecules

Based on the detection of productive viral infections in ciliated and goblet cells, we sought to identify
the cells that contributed the most to viral spread. We noticed a small but distinct cluster of ciliated cells
with an extremely high viral load (Fig. 2h, Extended Data Fig. 2b), in which we detected >1000 viral
RNAs per cell on average. Other infected cells typically contained <10 detectable viral RNAs.
Strikingly, while this hyper-infected subcluster of ciliated cells represents only 4% of all infected cells,
they contained 67% of all detectable viral RNA, uncovering an important role for this subset of ciliated
cells in fueling the viral spread.

243

244 To investigate how the varying amounts of virus per cell affects host cell gene expression, and vice 245 versa, we correlated the amount of viral RNA with the expression of host genes. This revealed that 246 ciliated cells exhibited a unique response to high viral amounts, upregulating AP1 and NFKB signaling, and multiple genes with known anti-inflammatory functions such as ERG1¹¹, NFKBIA¹², GDF15¹³, 247 HES1¹⁴, PER1¹⁵, TNFAIP3¹⁶, and NR4A1¹⁷ (Fig. 2i). This suggests that SARS-CoV-2 is capable of 248 249 inducing an unique response state in hyper-infected ciliated cells that is in part anti-inflammatory, 250 possibly to enhance viral spread and survival. This is further supported by the attenuation of the 251 interferon response in hyper-infected ciliated cells (Extended Data Fig. 6c).

252

Ciliated cells exhibit multiple temporally restricted response states resulting in MHC class II presentation on infected cells

255 To further investigate the role of ciliated cells in the local response to SARS-CoV-2 infection, we 256 delineated the ciliated cell compartment into five distinct cell states. In addition to the above-mentioned 257 interferon-stimulated, infected, and hyper-infected clusters, we detect a relatively abundant subset of 258 ciliated cells with high expression of acute-phase response (APR) genes such as SAA1. Interestingly, 259 these APR+ ciliated cells are present before inoculation, and increase the day after inoculation to up to 260 50% of all ciliated cells in participants with sustained infections (Fig. 2g). At day 3 post-inoculation, 261 interferon-stimulated ciliated cells emerge and peak at day 5, at which time point APR+ ciliated cells 262 have disappeared completely. At day 5, infected and hyper-infected ciliated cells start appearing, which 263 peak at day 7 post-inoculation. At day 10-14, interferon-stimulated cells decrease but remain higher 264 than baseline, while APR+ ciliated cells reemerge. Of note, APR+ ciliated cells are also immediately 265 upregulated in abortive but not transient infections, while all other ciliated cell states are uniquely 266 present in sustained infections only (Extended Data Fig. 7c).

267

268 Together, this underscores the highly dynamic nature of the ciliated cell compartment, and uncovers a 269 potential early response role for APR+ ciliated cells. Interestingly, infected but not hyper-infected, 270 ciliated cells also activate APR genes, and both APR+ and APR+/SARS-CoV-2 infected ciliated cells 271 express MHC class II (Extended Data Fig. 6c). While epithelial cells normally only express MHC 272 class I to present antigens to CD8+ T cells, there is evidence that viral infection can also induce MHC class II expression in epithelial cells¹⁸, despite classically being thought to be an exclusive feature of 273 274 professional antigen presenting cells. The colocalization of MHC class II+ ciliated cells with CD4+ T helper cells has also previously been reported¹⁹. This therefore raises the possibility that MHC class II 275 276 expression in infected ciliated cells could allow these cells to present SARS-CoV-2 antigens to antigen-277 specific CD4+ T cells.

278

279 Identification of activated T cells

To investigate the anatomic and temporal distribution of CD4+ and CD8+ T cells following infection, we annotated the T cell compartment in the blood and nasopharynx at high resolution into 54 distinct T cell states (**Fig. 3a,e**). Strikingly, these included subtypes of CD4+, CD8+ and regulatory T cell states that highly expressed T cell activation markers such as *CD38*, *CD28*, *CD27* and *ICOS* (**Fig. 3b**). While we and others have previously been unable to separate T cells that become activated during SARS-CoV-2 infection without enrichment experiments, we detected these activated T cells as distinct clusters

286 in both the circulating and nasopharyngeal T cell compartments. Reassuringly, many nasopharyngeal 287 and circulating activated T cells expressed the same TCR sequences (Extended Data Fig. 6d), showing 288 that they originated from the same clones found both in circulation and nasopharynx as a response to 289 infection. In addition, the immune repertoires of activated T cells were significantly more restricted and 290 clonal than other mature T cell types (Extended Data Fig. 6k), suggesting that they were activated and 291 expanded in a TCR- and antigen-specific manner. As expected from activation through TCR signaling, 292 we also detected high frequencies of cycling T cells within the activated T cell compartment. Of note, 293 we also detected many activated T cells that were not cycling, as well as cycling T cells that did not 294 appear to be activated, implying that our activation signature was at least partially independent of the 295 cell cycle gene signature. To test if these newly identified activated T cells are antigen-specific and can 296 recognize SARS-CoV-2 peptides, we performed peptide-MHC-I stainings on PBMCs using DNAbarcoded Dextramers loaded with SARS-CoV-2 antigens to detect peptide-MHC-I binding in parallel 297 298 with scRNAseq and scTCRseq. These experiments reveal that activated T cells are significantly enriched and indeed specifically bind SARS-CoV-2 peptides compared to unmatched peptide-MHC-I 299 300 molecules (Extended Data Fig. 7d-f, 8b). Together, the identification of activated T cells and their 301 transcriptome signature in unsorted PBMC and tissue samples presents a unique opportunity to study 302 the T cell response to SARS-CoV-2 in unprecedented detail.




Figure 3: Adaptive immune responses emerge at day 10 post-inoculation. (a) UMAP of all circulating T cells, highlighting the distinct cluster of activated T cells. Cells are color coded and labeled by their detailed cell state annotation. (b) Marker gene and protein expression of activated T cell subsets are shown in blue and red, respectively. (c) Percentages of nasopharyngeal T cells that were annotated as activated T cells, split over days since inoculation and color coded by infection group. (d) Boxplot as in (c), but showing circulating activated T cells. (e) UMAP as in (a), but showing nasopharyngeal T cells. (f) Fold changes in cell state abundance compared to pre-inoculation of nasopharyngeal and circulating conventional T cells are shown in the left and right plots, respectively. Only cell states that significantly change at a FDR < 10% at least one time point are shown. Nasopharyngeal T cell abundances were scaled to the total amount of detected epithelial cells. Fold changes and significance were calculated by fitting a GLMM as shown in Figure 1. The mean cell type proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the interpretation of changes in cell type abundances. (g) TCR clonality and expansion at day 14 of activated TCRs was validated using bulk TCR sequencing. For TCRs that matched the single cell gene expression, normalized clonality TCR alpha (left) and beta (right) data is separated by type and expressed as the average fraction of total clones in sample contributed by a cell of that type, with changes over time implying clonal expansion or contraction. For activated T cell types of interest, scatterplots for each sustained infection and at each time point sampled (days -1, 7, 14) are drawn. (h) Proportion of CD8+ infiltrating T cells that use alpha/beta TCRs, typical Dv2/Gv9 g/d TCRs, or atypical g/d TCRs is shown. (i) The relative immune repertoire composition of g/d T cells in circulation and nasopharynx after challenge are shown in the left and right bars, respectively. G/d chain pairs that are significantly more or less abundant between circulation and nasopharynx (p<0.05) are highlighted with an asterisks. (j) Dotplot as in (f), showing the fold changes in B cells. Legend for significance and mean cell type proportions as in (f). (k) Abundance of TCR clusters relative to all TCRs are shown over time since inoculation. Activated TCR clusters are color coded and their TCR motifs are shown. Legend for the physicochemical properties of amino acids in shown TCR motifs is shown in panel (1). (1) Plot as in (k), but showing BCR clusters. Immunoglobulin class usage within each activated BCR cluster is shown in the rightmost bars.

305

304

306 Activated T cells expand and peak ten days after inoculation

307 To better understand the characteristics of the activated T cells described above we quantified their 308 abundance over time and across infection groups (Fig. 3c-d,f). This revealed highly significant 309 expansions of activated CD4+ and CD8+ T cells peaking in both blood and nasopharynx at day 10 after 310 inoculation. This expansion was highly time-restricted, only appearing in the circulation after day 7 and 311 contracting rapidly thereafter. While this decrease meant that activated T cells were barely detectable 312 at day 28 post-inoculation, the associated TCR clonotypes in circulation could still be identified, having 313 transitioned into memory and effector T cells (Extended Data Fig. 6e). We integrated our single cell 314 resolved T cell data with highly sensitive bulk TCR sequencing from the blood to validate that activated 315 T cell-associated TCR sequences indeed clonally expand after day 7 post-inoculation in sustained (Fig. 316 3g) but not in abortive infections (Extended Data Fig. 6f). The emergence of these cells at day 10 after 317 inoculation closely resemble the temporal dynamics of a typical antigen-specific adaptive immune 318 response to vaccination and infection. At this time point we also observed clearance of detectable virus 319 and a reduction of IFN stimulation in the nasopharynx, suggesting that the onset of an adaptive T cell 320 response is associated with clearance of the infection. Importantly, activated T cells emerged in all

sustained infected participants, but in none of the abortive infections, underscoring their specificity to
infection. We did however detect a small increase of activated T cells in the nasopharynx of two of the
three transiently infected individuals (Fig. 3c), which might suggest that a smaller T cell response can

- be established without going through a sustained infection.
- 325
- In contrast to activated CD4+ and CD8+ T cells whose infiltration peaked at day 10, the amount of activated regulatory T cells was highest at day 14 at the site of infection (**Fig. 3c**), where they strongly upregulated expression of the anti-inflammatory cytokine IL-10 (**Fig. 3b**). This peak of activated regulatory T cells coincided with resolution of the observed global immune infiltrate (**Fig. 1f**) and downregulation of the IFN-stimulated response (**Fig. 2a**), suggesting a role for these regulatory T cells in suppressing further local inflammation after the infection has been cleared.
- 332

Interestingly, the time window during which activated CD8+ T cells were increased was broader in blood (**Fig. 3d**), while activated CD4+ T cells were detected for longer in the nasopharynx (**Fig. 3c**). In addition, activated CD4+ T cells were also significantly more abundant at the site of infection where they represent up to 15% of all nasopharyngeal-resident T cells at day 10 after inoculation. The predominance of activated CD4+ T cells in the respiratory mucosa was surprising, as CD8+ T cells are classically understood to be the major effectors in the local cytotoxic response. These results suggest that CD4+ T cells may play an unexpected and important role as local effectors.

340

341 Activated CD4+ T cells express cytolytic proteins

342 Activated CD4+ T cells express high amounts of cytotoxicity genes (e.g. PRF1, see Fig. 3b and 343 Extended Data Fig. 3a & 4a) that are normally expressed in NK and CD8+ T cells. As CD4+ T cells 344 can only recognise antigens in MHC class II context that is normally exclusive to professional antigenpresenting immune cells, the function and relevance of cytotoxic CD4+ T cells remains poorly 345 346 understood. However, several studies have reported their emergence during the adaptive immune response against SARS-CoV- $2^{20,21}$, and they have been reported to have a specific and antiviral effector 347 function in influenza challenge models²². It is therefore conceivable that the activation of cytotoxic 348 349 CD4+ T cells upon SARS-CoV-2 infection could potentially be a response to MHC class II presentation 350 by infected ciliated cells (Extended Data Fig. 6c). This would potentially enable antigen-specific 351 destruction of infected ciliated cells by CD4+ T cells (Fig. 2g).

352

353 Atypical g/d T cells infiltrate site of infection and dominate the g/d T cell response

354 In the nasopharynx, we also detected a subset of CD4+ and CD8+ T cells lacking both activation and 355 tissue-residency markers (such as ITGAE or CD103, Extended Data Fig. 3a) which appeared in the nasopharynx during sustained infections and which were annotated as "infiltrating memory T cells" 356 357 (Fig. 3e). We noticed that infiltrating CD8+ T cells expressed relatively few detectable alpha/beta TCRs 358 and had heterogenous CD8 expression, similarly to the gamma/delta (g/d) T cells that we had already 359 detected (Extended Data Fig. 2a). To investigate if this infiltrating subset harbors a distinct g/d T cell 360 population, we performed targeted single cell sequencing of the g/d TCR genes in the nasopharynx and 361 blood. This revealed that infiltrating CD8+ T cells indeed predominantly express g/d TCRs (Fig. 3h). 362 As expected, the g/d TCR repertoire found in circulating blood cells consists mostly of TCR chains 363 containing variable segments TRDV2 and TRGV9 (Fig. 3i). Strikingly, the nasopharynx is significantly 364 depleted for TRDV2/TRGV9+ T cells, with other variable segments dominating the g/d TCR repertoire. 365 More than 97% of the g/dTCR expressing infiltrating CD8+ T cells express these rare non-366 TRDV2/TRGV9 TCRs (which we termed atypical g/d T cells; Fig. 3h), which means that the atypical 367 g/d T cell response is four times more abundant than the typical g/d T cell response. While the exact 368 function of atypical g/d T cells is still poorly understood, their timing alongside other adaptive immune 369 responses and its restriction to sustained infections, suggests that they might play an underappreciated 370 role in the immune response against SARS-CoV-2 infection.

371

372 Antibody secreting B cells clonally expand ten days after exposure

373 Given that the strong T cell response that appears highly time restricted to day 10 post-inoculation, we 374 hypothesized that there should be a B cell response at a similar time point. To test this, we investigated 375 the temporal and cell state dynamics of the B cell response to SARS-CoV-2 inoculation. We detected 376 distinct subtypes of naive, memory and antibody-secreting B cells (plasmablasts and plasma cells), and 377 used the BCR data to distinguish immunoglobulin class and isotype switching (Extended Data Fig. 378 **4b**). In line with the observed T cell response, we observe a strong and highly time restricted B cell 379 response from day 10-14 after SARS-CoV-2 exposure (Fig. 3j). In blood, this response includes a clear 380 switch from naive and IgG/IgA memory B cells to mostly IgG1 and some IgA1 secreting plasmablasts 381 and plasma cells. IgA1 and IgG1 are expected to be the dominant antibody immunoglobulin classes in blood²³, and the timing of production of antibodies is in line with B cell responses observed in 382 vaccination studies²⁴, suggesting that these antibody secreting B cells at day 10 after inoculation are 383 384 SARS-CoV-2 specific. While numbers of detected B cells in the nasopharynx are limited, we also 385 observe significant infiltration of both IgA+ and IgG+ B cells into the nasopharynx from day 10 post-386 inoculation (Fig. 3i), indicating that the B cell response leads to antibody production at the site of 387 infection. Together, these findings suggest that it takes ten days from SARS-CoV-2 exposure for the

adaptive immune response to mature and expand to detectable abundances. Importantly, we show a
 concerted adaptive immune response of B and T cells at both local and systemic level, which is
 facilitated by antibody secreting and activated lymphocytes.

391

392 Cell2TCR: Identification of clonotype groups that are likely SARS-CoV-2 specific

393 We next set out to leverage the transcriptomically distinct B and T cell states that are associated with 394 the adaptive immune response, to identify BCR and TCR clonotypes that specifically recognise SARS-395 CoV-2 (see *Methods* for details). We designed a cell state-driven approach that enabled us to detect the 396 permitted divergence between TCR or BCR sequences in an antigen-specific response. To this end, we 397 quantified the inclusion of naive B and T cells, and the mixing of CD8+ and CD4+ T cells, to quantify 398 the impurity of TCR and BCR clonotype groups (groups of B and T cells that express highly similar 399 BCR or TCR sequences). We next selected activated clonotype groups that appear to expand in an 400 antigen-specific manner (i.e. express multiple independent but highly similar TCR/BCR sequences in 401 activated T cells or antibody-secreting B cells). Reassuringly, this clonotype selection method 402 exclusively yields activated clonotypes in participants with sustained infections (Extended Data Fig. 403 6g-h). In total, we detect 20 activated TCR clonotype groups and 15 activated BCR clonotype groups 404 in the six participants with sustained infections (Fig. 31). These clonotype groups first emerge after 1 405 week, most appear at day 10, and some remain detectable at day 28 post-inoculation. When we applied 406 Cell2TCR on all activated CD8+ T cells as well as all HLA-matched CD8+ T cells from the Dextramer 407 assay, we found 14 clonotype groups that contained cells from both datasets, validating the specificity 408 and annotating the recognized antigen of these clonotype groups (Extended Data Table 1c).

409

Interestingly, even at the peak of expansion at day 10 post-inoculation, all but one of the activated clonotype groups have only very low abundance (<0.001% of all T cells), at the detection limit of single cell genomics approaches. Such low prevalence makes activated clonotypes difficult to detect and distinguish from bystander cells when simply performing enrichment analysis of the entire immune repertoire between healthy and infection samples. This highlights the importance of considering single cell phenotypes in VDJ analyses and the usefulness of our newly identified activated T cell state.


416

Importantly, in contrast to activation or enrichment assays that require *in vitro* incubation with antigens^{25,26}, our Cell2TCR approach for detecting clonotypes that are activated in a disease of interest is not restricted and biased towards known antigens. Hence, it can be applied to any infection, inflammatory disease or cancer single cell RNA- and VDJ-seq dataset to extract paired chains recognising antigens.

422

Integrating COVID-19 patient data uncovers public SARS-CoV-2 TCR motifs 423

424 We hypothesized that our deep characterization of the adaptive immune response in PBMCs could be 425 leveraged when analyzing patient COVID-19 data, in particular to study activated T cell states and 426 associated SARS-CoV-2 specific TCR repertoires. To this end, we integrated our data together with 427 single cell RNA-seq data from five large-scale studies that profiled PBMC samples using a deep 428 generative model (scVI variational autoencoder, see *Methods*), and obtained just short of one million T 429 cells from several hundred individuals, including over 240 acute COVID-19 patients (Extended Data Table 1d,e). We next projected our highly detailed cell type annotation, including the activated T cell 430 states, onto the patient data (Fig. 4a and 4c). This revealed that activated T cells are also present in 431 COVID-19 patients that were sampled outside a viral challenge setting, and that these activated subsets 432 433 also form distinct clusters of cells within the T cell compartment. Importantly, the fraction of activated 434 T cells was significantly higher in COVID-19 patients and convalescence samples compared to healthy 435 controls, underscoring their involvement in the immune response to COVID-19 (Fig. 4b).



Moderate

- Mild

= 0.61

Spearman r

20 30 40 50

Self reported days since onset symptoms

Predicted c to SARS-

436

Figure 4: Integrating COVID-19 patient data reveals public SARS-CoV-2 TCR motifs

(a) UMAP representation after integration of five COVID-19 patient datasets with paired RNA and VDJ sequencing data. Cell type labels inferred using a logistic regression classifier (Celltypist) trained on manual annotations of PBMCs from the current work. (b) Fraction of activated T cells across all T cells in sample for COVID-19 (n = 240), convalescent (n = 240), convalescent (n = 240), convalescent (n = 240), convalescent (n = 240), converse to the converse of the converse o 82) and healthy (n = 88) samples of five COVID-19 patient datasets. Significance levels after Mann-Whitney testing are shown and indicate that COVID-19 and convalescent samples have significantly more activated T cells than healthy samples. (c) Activated T cell types highlighted on UMAP representation from panel (a). Activated CD8+ T cells were most abundant, followed by CD4+ and regulatory types, and clustered together in a distinct area of the latent space. (d) Clustermap of pairwise TCR distances with color-coded information for each TCR on patient id, study, motif, antigen on the left-hand side, as well as the sequence logos for the nine most common motifs on the right-hand side. Each column/row corresponds to a unique TCR, and the distance to each TCR in the set is indicated by color. Only activated T cells with public motifs (identified in more than one individual) were considered. Low distances indicate similar TCRs, with distances of 40 and less potentially yielding TCRs recognising the same epitopes. For sequence logos, letter height indicates frequency of AA at that position across T cells pertaining to the motif. AAs are colored by side chain chemistry: Acidic (red), basic (blue), hydrophobic (black), neutral (purple), polar (green). AA: amino acid. (e) Recorded symptoms averaged over SARS-CoV-2 challenge participants with sustained infection for days -1 to 14 post-inoculation. Major molecular events in the immune response are highlighted with arrows. (f) Predicted time since viral exposure is plotted against reported time since onset of symptoms. Lines represent loess fits of the data split and color coded by reported severity.

438

437

439 We then employed our cell state aware clonotype group selection approach (Cell2TCR) to identify 440 activated clonotypes, which resulted in 254 COVID-19 associated clonotype groups (Extended Data 441 Table 1f). Strikingly, 211 of these activated clonotype groups were shared between patients (largest 442 groups shown in Fig. 4d), highlighting the antigen-specificity of this approach, with the two most 443 common motifs being shared by 13 individuals each. This also implies that a relatively small set of 444 highly immunogenic SARS-CoV-2 peptides results in most of the T cell responses in COVID-19. 445 Finally, we wanted to validate the antigen-specificity of the COVID-19 associated clonotype groups 446 that we found in the public and challenge study data. Thus we intersected the CDR3 amino acid 447 sequences with databases containing experimentally validated SARS-CoV-2 specific TCRs (see 448 Methods). Importantly, this revealed that activated clonotype groups, including groups that contain TCRs from this study, are 3.75 fold enriched ($p = 1.68 \times 10^{-21}$) for SARS-CoV-2 specific TCRs. This 449 450 provides strong validation for activated T cells indeed representing the antigen-specific T cell response 451 against SARS-CoV-2 (Extended Data Fig. 6i). Most of the activated T cell clonotype groups recognise 452 viral proteins encoded by ORF1ab, but we also find Membrane and Spike specific TCR clonotype 453 groups. Because our cell state aware clonotype selection method identifies SARS-CoV-2 specific TCRs 454 without any prior antigen information, our results may also include TCRs that recognise SARS-CoV-2 455 antigens that have not yet been tested. Together, these results validate the specificity of the adaptive

immune response that we observed at day 10, and highlight the power of defining activated T cells fordetecting disease-specific antigens in an unbiased manner.

458

459 Molecular responses precede and are dynamic during clinical manifestations

460 Last, we wanted to investigate how our single-cell resolved timeline of immune responses relates to 461 clinical manifestations that are typically observed and measured in COVID-19 patients. The unique 462 experimental setting of our human challenge model enabled us to collect highly detailed and time-463 resolved clinical data for all participants that were profiled using single cell genomics approaches. The 464 timing of the most relevant and dynamic COVID-19 symptoms show that even the earliest symptoms 465 appear mostly at day 4 post-inoculation (Fig. 4e), which is later than some of the molecular responses 466 that we described. Here, the upregulation of APR in ciliated cells, the activation of MAIT cells, 467 depletion of some myeloid cells, and the global activation of IFN signaling in blood are observed before 468 or at day 3 post challenge (Fig. 2). In contrast, a slight rise in temperature is only significantly detectable 469 at day 4 post-inoculation ($p = 5 \times 10^{-6}$), at which early upper airway-related symptoms such as a stuffy 470 nose and a sore throat also appear. This is then followed by global immune infiltration and activation 471 of IFN signaling at the site of infection at day 5, which is also the first time that we detected infected 472 cells. This coincides with a slight increase in C-reactive protein (CRP) in blood (p = 0.04). At day 7 473 post-inoculation we observed that the amount of detectable infected cells peaked. Interestingly, from day 8 on we also observed that all but one of the participants with a sustained infection significantly 474 lost their sense of smell (p = 0.004), together with aggravation of sneezing and a stuffy nose. This was 475 476 followed by a strong reduction in the amount of infected cells at day 10 and a peak in the amount of 477 nasopharyngeal immune infiltration, which coincides with the onset and expansion of an adaptive 478 immune response and clearance of most symptoms. In summary, we observe that clinical manifestations 479 and different waves of immune responses dynamically change over time, which can aid the molecular 480 interpretation of COVID-19 based on clinical observations and improves our understanding of the 481 therapeutic time windows in this disease.

482

483 Human COVID-19 challenge data as a reference atlas for cell dynamics

To maximize the impact of our time-resolved COVID-19 dataset, we build predictive models to infer time since SARS-CoV-2 exposure. We used Gaussian process regression and latent variable models to fit the changes in cell state composition during sustained infection. We next applied these predictions to publicly available PBMC single cell RNA-seq datasets from 361 COVID-19 samples, to infer at which stage of the immune response each patient was and to predict when this patient was exposed to SARS-CoV-2. Reassuringly, our Gaussian processes based time inference model predicts that the time since exposure and the time since onset of symptoms are highly correlated (**Fig. 4f**), and that exposure

491 is predicted to precede onset of symptoms, as expected. Interestingly, the predicted difference between 492 exposure and symptoms decreases with increased severity (Extended Data Fig. 6j), where patients 493 with more severe COVID-19 are predicted to be in the adaptive immune reaction phase for longer. 494 While this suggests that patients with severe COVID-19 take longer to clear the virus, it could also 495 indicate that the cellular composition and immune response timeline in severe cases is perturbed 496 compared to the relatively mild cases observed in the challenge study. In addition to a temporal model 497 that could improve the assessment of the disease stage of COVID-19 patients, we also provide 498 annotation models for a total of 202 cell states including new temporal and rare cell states. These models 499 are now included in the default models at Celltypist.org, and enable highly detailed cell type annotation 500 without the need for bioinformatics expertise. In addition, our single cell expression data is freely 501 available at our COVID19CellAtlas.org web portal for online exploration and analysis.

502

503 Discussion

504 Our findings have implications for the COVID-19 and broader infection diseases community. We detect 505 multiple response states that precede the onset of clinical manifestations, including the activation of 506 MAIT cells and decreases in inflammatory monocytes. Importantly, this represents a newly discovered 507 immune response that emerges when an individual is exposed to SARS-CoV-2, but manages to prevent 508 the onset of viral spread. These features of very early and abortive infections can be used as biomarkers 509 and help to understand the immediate immune response upon viral exposure. In addition, we discovered 510 a distinct cell state for activated conventional T cells that harbor SARS-CoV-2 specific TCRs, and we 511 show that this signature can be projected onto patient cohort data to unravel the disease specific T cell 512 response.

513


514 The timing of our challenge experiments in the early stages of a pandemic with a new virus - before 515 most of the population acquired immune memory through natural infections and vaccine rollout -516 enabled us to recruit and study immune responses in adult participants that were completely naive to 517 this pathogen. The resulting unique data will be essentially impossible to replicate in future efforts as 518 the population builds memory to many SARS-CoV-2 strains. In addition to the responses during 519 sustained infections and COVID-19, we were also able to study abortive and transient infections that 520 would be extremely challenging to detect outside a controlled challenge setting, revealing novel 521 immune response signatures associated with successfully preventing sustained infections.

522

523 Our results uncovered a temporally resolved timeline of antiviral responses in epithelial and immune 524 cells both locally at the site of infection and systemically in circulation (**Fig. 5**). During sustained

525 infections that lead to COVID-19, we observe an immediate and novel acute phase response in ciliated 526 cells at the site of infection. In blood, we observe two novel innate immune responses in which MAIT 527 cells become activated, and inflammatory monocytes migrate out of circulation. These two responses 528 are the only immune responses that are also observed in participants with abortive infections that did 529 not develop COVID-19, underscoring their importance and sensitivity, and uncovering a new and 529 https://www.acuteur.com/sensitivity/sensitivi





531

Figure 5: Temporally resolved epithelial and immune response in SARS-CoV-2 infections

Summary figure highlighting 1) temporal differences in the distinct infection groups, 2) novel antiviral responses, 3) novel characteristics of sustained infection, and 4) the identification of public motifs in SARS-CoV-2 specific activated T cells. In addition, our work provides community tools for inference of specific TCR motifs (Cell2TCR) in activated T cells, and for temporal assignments of clinical COVID-19 samples underpinning future therapeutic applications.

532 533

In sustained infections, we observe global activation of interferon signaling that affects all circulating 534 535 immune cells. Strikingly, the activation of interferon signaling in blood precedes widespread activation 536 at the site of inoculation, which suggests that a highly efficient relay to the systemic immune system 537 exists, likely through the lymphatic system. The activation of interferon signaling at day 5 to seven 538 post-inoculation coincides with global immune infiltration and a peak of detectable virally infected 539 cells. This relatively slow immune response at the site of inoculation is in contrast to the immediate 540 immune infiltration that we observed in infections that were only transiently detectable. In sustained 541 infections, we also detect large amounts of cells containing viral RNA including infection of immune

cells, but we provide evidence that only epithelial cells support successful viral replication. Here, we
found that a small subset of hyper-infected ciliated cells becomes anti-inflammatory and the main
source of viral production.

545

546 While our experimental approach included matched preinfection samples and we profiled all expected 547 cell types from a total of 181 samples from 16 participants, we cannot exclude the possibility that our 548 infection group sizes remained underpowered to detect very subtle or time-restricted responses. In 549 addition, we note that the participants enrolled in this study cleared the infection with mild symptoms. 550 It is possible that COVID-19 patients that require hospitalization exhibit perturbed or exacerbated 551 immune responses that were not captured in our work, which could mean that caution should be taken 552 when extrapolating our findings to critically ill COVID-19 patients.

553

554 At day 10 post-inoculation, we detect the onset and expansion of the adaptive immune response. In 555 addition to antibody-secreting B cells, this response also includes activated conventional T cells. This 556 is the first time to our knowledge that these cells have been described in single cell transcriptomics 557 assays, likely because of the limited time window in which these activated T cells are detectable. Two 558 weeks after inoculation, the amount of activated regulatory T cells at the site of inoculation peaks, while 559 the abundance of other immune cells normalizes again, which coincides with a near absence of any 560 remaining infected cells. These activation states have key marker genes, and we can identify these 561 activated CD4+, CD8+, and regulatory T cell states using machine learning models. We integrate their 562 prediction into a computational pipeline (Cell2TCR) which includes paired chain TCR motif inference. 563 This is a tool applicable to any single cell RNA/VDJ dataset of infection, inflammation or tumor 564 immune response.

565

566 Together, this represents the most comprehensive and detailed time-resolved description of the course

- 567 of SARS-CoV-2 infection, or any other infectious disease, and gives unique insights into responses that
- are associated with resisting a sustained infection and disease.

569 Acknowledgements

570 We are grateful to Sheila Casserlya and Sujana Regmi for assistance with collecting samples, and 571 Tarryn Porter, Agnes Oszlanczi, Yvette Wood and Sabine Eckert for library preparation. We thank Rasa 572 Elmentaite for helpful discussions on activated T cells. We acknowledge assistance from Rea Dabelić 573 (10X Genomics), Illumina and 10X Genomics. We are grateful for the support and guidance with 574 MACS for the Dextramer work provided by Yanping Guo, the Flow Cytometry Translational 575 Technology Platform Manager at UCL Cancer Institute. We acknowledge assistance provided by the 576 University College London CL3 facility at the Paul O'Gorman building and the staff at the Sanger 577 Institute Core Sequencing facility.

578

579 This research was funded in whole, or in part, by the Wellcome Trust Grant 206194, 220540/Z/20/A 580 and 211276/Z/18/Z, and by Action Medical Research (GN2911, to M.Z.N. and K.B.M.). M.Z.N. 581 acknowledges funding from a MRC Clinician Scientist Fellowship (MR/W00111X/1). M.Z.N. and 582 J.L.B. acknowledge funding from the Rutherford Fund Fellowship allocated by the MRC UK 583 Regenerative Medicine Platform 2 (MR/5005579/1). M.Y. was funded by The Jikei University School 584 of Medicine and Action Medical Research (GN2911). K.B.W. acknowledges funding from University 585 College London, Birkbeck MRC Doctoral Training Programme, L.M.D is supported by the European 586 Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant 587 agreement No 955321. M.N. acknowledges funding from the Wellcome Trust (207511/Z/17/Z) and by 588 NIHR Biomedical Research Funding to UCL and UCLH. R.H. is a NIHR Senior Investigator.

589

For the purpose of Open Access, the author has applied a CC BY public copyright license to any AuthorAccepted Manuscript version arising from this submission.

592

593 Author Contributions

594 M.Z.N. and S.A.T. conceived, set up, directed this study and provided funding. C.C. set up the clinical 595 study and co-ordinated sampling, K.B.W. optimized digestion protocols, processed samples for 10X 596 and CITEseq, isolated DNA for genotyping, performed Dextramer experiments and assisted with data 597 analysis and interpretation. R.G.H.L. performed and led the data analysis. L.M.D. assisted with data 598 analysis. R.G.H.L., K.B.W., L.M.D., K.B.M., M.Z.N. and S.A.T. interpreted the data and wrote the 599 manuscript. M.Y., J.L.B., J.A.H. assisted with 10X sample processing. V.T., S.M.J. and R.C.C. 600 provided student supervision to K.B.W. and PM.. H.R.W. processed blood samples. P.M. collected 601 nasopharyngeal samples for optimisation of digestion protocols. M.H., M.N. and R.H. assisted in the

602	set up of the study	. B.K., M.K., A.C.	, A.B	and M.M.	oversaw	sample	collection an	d provided	l clinical

603 data.

604

605 These authors contributed equally: Rik G.H. Lindeboom, Kaylee B. Worlock

- 606 These authors jointly supervised this work: Marko Z. Nikolić, Sarah A. Teichmann
- 607

608 Data Availability

- The data presented in this study can be explored and analyzed interactively through our COVID-19 Cell
- 610 Atlas web portal (<u>https://covid19cellatlas.org</u>), currently accessible via early-access at <u>http://covid19-</u>
- 611 <u>challenge-study.cellgeni.sanger.ac.uk/</u> until publication in a peer reviewed journal. The cell by feature
- 612 count matrices are also available to download at the web portal. The cell state annotation models are
- 613 available in the CellTypist model repository (<u>https://www.celltypist.org/models</u>). A reference for our
- 614 MT-GPR model to infer time since viral exposure on PBMC data is available at our GitHub repository
- 615 (<u>https://github.com/Teichlab/COVID-19_Challenge_Study</u>). The raw sequencing data will be made
- available before publication in a peer-reviewed journal via the European Genome-Phenome Archive,which will be made available under managed data access.
- 618

619 Code availability

620 Cell2TCR is available at our GitHub repository (<u>https://github.com/Teichlab/Cell2TCR</u>). Code that was
621 used for data analysis is available at our GitHub repository (<u>https://github.com/Teichlab/COVID-</u>
622 19 Challenge Study).

623

624 Competing interest statement

625 R.G.H.L., L.M.D. and S.A.T. are inventors on a filed patent that is related to the detection and 626 application of activated T cells. In the past three years, S.A.T. has received remuneration for Scientific 627 Advisory Board Membership from Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-628 founder and holds equity in Transition Bio. P.M. is a Medical Research Council (MRC)-629 GlaxoSmithKline EMINENT clinical training fellow with project funding unrelated to the topic of this 630 Comment and receives co-funding from the National Institute for Health Research (NIHR) University 631 College London Hospitals (UCLH) Biomedical Research Centre. P.M. reports consultancy fees from 632 SOBI, AbbVie, UCB, Lilly, Boehringer Ingelheim, and EUSA Pharma all unrelated to this submission.

633 A.M., A.C., M.K., M.M. and A.B. are full time employees at hVIVO Services Ltd.

634 Methods

635

636 Study participants and design

637 16 healthy adults aged 18-30 years, with no evidence of a previous SARS-CoV-2 infections or 638 vaccinations (seronegative), were included for this study from the wider cohort (34 participant) enrolled 639 as part of the Human COVID-19 Challenge study, pioneered by the government task force, Imperial 640 college london, Royal Free London NHS Foundation Trust and hVIVO⁶. These participants were 641 enrolled as part of the cohort 5 and 6, from June - August 2021. Reported patient identifiers have been 642 de-identified and are not known by the participants in this study. Volunteers were tested for the presence 643 of anti-SARS-CoV-2 protein antibodies via the MosaiQ COVID-19 antibody microarray (Quotient) 644 prior to enrollment and excluded based upon a positive test, as well as, upon risk factors assessed by 645 clinical history, physical examinations and screening assessments. See Killingley, Mann et al. $(2022)^6$ 646 for the full list of inclusion and exclusion criteria and for further details regarding the challenge set up 647 and ethics. In short, written informed consent was obtained from all volunteers before screening and 648 study enrollment. The clinical study was registered with ClinicalTrials.gov (identifier NCT04865237). 649 This study was conducted in accordance with the protocol, the Consensus ethical principles derived 650 from international guidelines including the Declaration of Helsinki and Council for International 651 Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable ICH Good 652 Clinical Practice guidelines, applicable laws and regulations. The screening protocol and main study 653 were approved by the UK Health Research Authority – Ad Hoc Specialist Ethics Committee (reference: 654 20/UK/2001 and 20/UK/0002).

655

Participant 674007, who fulfilled enrollment criteria, was later found to have low levels of neutralizing and spike-binding antibodies on admission to the quarantine upon more sensitive post-study experiments and analysis. This patient was classified as an abortive infection based on the virus kinetics (see virology method below), with the exclusion of this individual found not to alter any of our conclusions.

661

662 The participants were followed for 1 year after inoculation, with continued samples and metadata 663 collected for the use in future/further studies and to benefit the research community. This study however 664 focused primarily on the first 28-days post-inoculation (with the exception of 46 days for one participant 665 as noted below, see Sample collection).

666

667 Challenge virus

668 Participants were inoculated intranasally with an wild-type pre-alpha SARS-CoV-2 challenge virus (full 669 formal name: SARS-CoV-2/human/GBR/484861/2020) at dose 10 TCID50 at day 0. 100 µl per naris 670 was pipetted between both nostrils and the participant was asked to remain supine (face and torso facing 671 up) for 10 minutes, followed by 20 minutes in a sitting position wearing a nose clip after inoculation to 672 ensure maximum contact time with the nasal and pharyngeal mucosa. Mid-turbinate nose and throat 673 samples were collected twice daily using flocked swabs and placed in 3 ml of viral transport medium 674 (BSV-VTM-001, Bio-Serv) that was aliquoted and stored at -80 °C in order to evaluate viral kinetics 675 (infection status) as described in Virology method section below. Participants remained in quarantine 676 for a minimum of 14 days post-inoculation until the following discharge criteria were met: two 677 consecutive daily nose and or throat swabs with no viral detection or a qPCR Ct value >33.5 and no 678 viable virus by overnight incubation viral culture with detection by immunofluorescence. For 679 protocol/full details and ethics used within the Human SARS-CoV-2 challenge study see the Challenge 680 virus section of methods in Killingley and Mann., et al $(2022)^6$.

681

682 Sample collection

683 Nasopharyngeal swabs

684 Samples were collected at the Royal Free Hospital by trained healthcare providers at 7 timepoints; day-685 1 (pre-inoculation) and day 1, 3, 5, 7, 10 and 14 post-inoculation. The patients were asked to clear any 686 mucus from their nasal cavities and nasopharyngeal samples were collected using FLOQSwabs (Copan 687 flocked swabs, Ref 501CS01) inserted along the nasal septum, above the floor of the nasal passage to 688 the nasopharynx until a slight resistance was felt. The swab was then rotated in this potion in both 689 directions for 10 seconds and slowly removed whilst still rotating and immediately stored in a pre-690 cooled cryovial on wet ice containing freeze media (90% heat inactivated fetal bovine serum (FBS) and 691 10% dimethyl sulfoxide (DMSO). On wet ice the cryovials vials were the transferred to the hospital 692 chutes where they were sent down to the laboratory (<2 mins at RT) and placed in a slow-cooling device 693 (Mr. Frosty Freezing Container, Thermo Fisher Scientific) and stored at -20 °C until all samples were 694 collected, at which point they were moved to -80 °C freezers for at least 48 hours for optimum freezing. 695 Samples were moved, stored and in liquid nitrogen for later processing.

696

697 *PBMC isolation from peripheral blood*

Peripheral whole blood was collected at the Royal free hospital in EDTA tubes at 5 timepoints; day-1
(pre-inoculation) and day 3, 5, 10, 14 and 28 post-inoculation. Each day the blood was transferred at
room temperature to Imperial College London for the fresh isolation and collection of peripheral blood

701 mononuclear cells (PBMC) by means of Histopaque Ficoll separation (Merck, H8889-500ML). The 702 peripheral whole blood was first diluted 1:1 with 1X PBS (Merck, D8662-500ML) before being gently 703 overlayed onto a maximum of 15 mL of Histopaque, at a ratio of 2:1 (blood:Histopaque). The samples 704 were then centrifuged at 400xg (with no breaks) for 30 min at room temperature (RT) and the PBMC 705 white buffer layer collected, washed (with PBS ~50 mL) and spun down (400xg for 10 min at RT), 706 before the supernatant was carefully discarded and the cell pellet was resuspended in 10 mL PBS. The 707 cells were filtered using a 40 or 70mm cell strainer and then both the cell number and viability were 708 assessed using Trypan Blue. The cells were further centrifuged (400xg for 10 mins) and resuspend in 709 the required volume of Cell Freezing Media; 90% FBS (Sigma, F9665-500ML), 10% DMSO (Sigma, 710 D2650-100ML), before being cryopreserved at -80 °C using a slow-cooling device. The blood and 711 nasopharyngeal samples were collected within 2 hours of each other.

712 Of note after their were discharged from quarantine and prior to their 28-day follow up (where additional 713 blood samples were collected), two participants reported either to have had their first SARS-CoV-2 714 vaccine (636163) or a community infection; 636163 had their first vaccine on day 14 post-inoculation 715 (2 weeks before the day-28 sample was taken). 677306 tested positive before their day 28 visit was due. 716 The follow up was therefore delayed by 2 weeks, resulting in the "day 28" sample for this participant 717 instead being taken day 46 post-inoculation. ELISpot performed on this participant revealed a response 718 in the day 28 and 90 samples (data not shown). Moreover, participant 677696 tested positive on day 29 719 post-inoculation, a day after their day 28 sample was taken. However for this participant the ELISpot 720 showed no response at day 28 and a small response at day 90 suggesting the day 28. See Extended 721 **Data Fig. 1a** for overview of the samples and timepoints included from each participant. These 722 individuals/timepoints were found not to alter any of our conclusions.

723

724 Clinical assessments

Participants were carefully monitored and assessed daily using an array of blood tests, spirometry,
electrocardiograms and clinical assessments (vital signs, symptom diaries and clinical examination).
Full details of all the safety and clinical data collected with the human SARS-CoV-2 challenge study
can be seen in the methods in Killingley and Mann., et al (2022)⁶, with an overview of select metadata
for the 16 participants enrolled in this study in Extended Data Table 1g.

730

731 Virology

732 Longitudinal measures from the nose and throat (pharyngeal) were carried out daily in order to assess
733 and quantify the viral kinetics of each participant pre- and post-inoculation. These were measured using
734 two independent assays: (1) qRT–PCR with N gene primers/probes adapted from the Centers for

Disease Control and Prevention (CDC) protocol²⁷ (updated 29 May 2020) and (2) quantitative culture
by Focus Forming Assay (FFA). For full details of each assay and statistical analysis refer to the
methods in Killingley and Mann., et al (2022)⁶.

738

The lower limit of quantification (LLOQ) for RT-qPCR was 3 log10 copies per milliliter, with positive detections less than the LLOQ assigned a value of 1.5 log10 copies per milliliter and undetectable samples assigned a value of 0 log10 copies copies per milliliter. Only samples where participants presented with a positive RT-qPCR were further tested using the FFA assay. In the FFA the LLOQ was 1.27 FFU ml-1; viral detection less than the LLOQ was assigned 1 log10 FFU ml-1; and undetectable samples were assigned 0 log10 FFU ml-.

745

A sustained laboratory-confirmed infection was defined as quantifiable RT–qPCR detection greater than the LLOQ from mid-turbinate and/or throat (pharyngeal) swabs on two or more consecutive 12hourly time points, starting from 24 hours after inoculation and up to discharge from quarantine. Participants where only stand alone RT–qPCR tests returned quantifiable results (> LLOQ) were classified as transient infections. Participants where no RT–qPCR tests returned quantifiable results (> LLOQ) were classified as abortive infections (See Extended Data Fig. 1b and Extended Data Table 1a,b,h,i).

753

754 Infection intervals for each participant were calculated based on the time of the first and last RT-

qPCR test with detectable virus (across the nose and/or throat), where timepoints in which tests below

the LLOQ (1.5) were also counted if they occurred < 2 days of a quantifiable (> LLOQ) test result.

757

758 Nasopharyngeal swab dissociation and processing

759 Following freezing, nasopharyngeal swabs were transferred to a category level 3 facility at University 760 College London were stored and processed in batches of 7-to -8 samples at a time to a single cell 761 suspension. All work was carried out in a MSC class I hood in compliance with standard category level 762 3 safety practices. The dissociation and collection of cells from nasopharyngeal swab was carried out in accordance with the previously described protocol 28,29 , with minor modifications. This approach 763 764 involves multiple parallel washes and digestion steps using both the nasopharyngeal swab and collected 765 freezing/ wash media to help ensure the maximum cells and cellular material is collected. First samples 766 are exposed to DTT for 15 mins, followed by an accutase digestion step for 30 mins before cells from 767 the same sample (collected directly from the swab or the freezing media/washes from that swab) are 768 quenched, pooled and filtered prior to checking the cell number and viability.

769

770 Briefly, samples were rapidly thawed and the liquid collected in an empty 15mL falcon tube (Tube B). 771 The cryovial, lid and swab was then carefully rinsed with 3x 1mL warm RPMI 1640 medium which 772 was added dropwise to the 15 mL tube whilst gently swirling the tube, in order to slowly dilute the 773 DMSO from the freezing media to help present the cells bursting. After waiting 1 min, the tube (Tube 774 B) was then topped up with an extra 2 mL of warm RPMI 1640 media and centrifuged at 400 g for 5 775 min at 4°C. The cell pellet was then resuspended in RPMI 1640/10 mM DTT (Thermofisher, R0861), 776 and incubated for 15 min on a thermomixer (37°C, 700 rpm), centrifuged as above and the supernatant 777 was aspirated and the cell pellet was resuspended in 1 mL Accutase (Merck, A6964-500ML). This was

- then incubated for a further 30 min on the thermomixer (37°C, 700 rpm).
- 779

780 In parallel to the processing of the cell freezing media/washes above, the swab was moved to an new 781 1.5 mL eppendorf tube (Tube C) containing 1 mL RPMI 1640/10 mM DTT and placed on the 782 thermomixer (37°C, 700 rpm) for 15 minutes. In accordance with the steps above, the swab was next 783 transferred to a new 1.5 mL eppendorf (Tube D) containing 1 mL Accutase and incubated with agitation 784 (700 rpm) at 37°C. The 1 mL RPMI 1640/10 mM DTT from the nasopharyngeal swab incubation (in 785 **Tube** C) was centrifuged at 400 g for 5 min at 4°C to pellet cells, the supernatant was discarded, and 786 the cell pellet was resuspended in 1 mL Accutase and incubated for 30 min at 37°C with agitation (700 787 rpm).

788

Following the Accutase digestion step, all cells were combined (Tube B, C and D) and filtered using a 70 μm nylon strainer (pre-wetted with 3 mL quenching media: RPMI 1640/10% FBS/1 mM EDTA (Invitrogen, 1555785-038) in a 50 mL conical tube (Tube E).

792 The filter, tubes and swab were then further thoroughly rinsed with quenching media in order to collect 793 all cells and the washes combined. The dissociated, filtered cells (Tube E) were then centrifuged at 400 794 g for 5 min at 4°C, and supernatant discarded. The cell pellet was resuspended in residual volume (~500 795 uL) and transferred to a new 1.5 mL eppendorf tube (**Tube F**). **Tube E** was then washed with a further 796 500 µL of RPMI 1640/10% FBS and combined with Tube F, centrifuged as above, supernatant removed 797 and cells resuspended in 20 µL of RPMI 1640/10% FBS. Using Trypan Blue, total cell counts and 798 viability were assessed. The cell concentration was adjusted for 7,000 targeted cell recovery according 799 to the 10x Chromium manual before loading onto the 10x chip (between 700–1,000 cells per μ l) and 800 processing immediately for 10x 5' single-cell capture using the Chromium Next GEM Single Cell V(D)J 801 Reagent Kit v1.1 (Rev E Guide). For samples where fewer than 13,200 total cells were recovered, all 802 cells were loaded.

803

Note: Due to the sample type, necessary freezing process and no access to a class 3 flow facility to sort
out viable cells, the majority of the samples processed were seen to have low viability (ranging from
5.4% viability to 57.85, with the average viability of samples processed of 26.89%).

807

808 PBMC CITE-seq staining for single-cell proteogenomics

809 Frozen PBMC samples were thawed and processed in batches of 16 to allow for a carefully designed 810 pooling strategy. Here each sample was pooled twice into two unique pools containing up to four PBMC 811 samples per pool from mixed timepoints. Note: Only one sample from each donor was even pooled 812 together at a time to assist with the demultiplexing later. This pooling strategy was used to help remove 813 and correct for any protocol-based batch effects.

814

In brief, PBMC samples were thawed quickly at 37 °C in a water bath. Warm RPMI 1640 medium (20–
30 mL) containing 10% FBS (RPMI 1640/FBS) was added slowly to the cells before centrifuging at
300g for 5 min. This was followed by a wash in 5 mL RPMI 1640/FBS. The PBMC pellet was collected,
and the cell number and viability were determined using Trypan Blue.

819

820 PBMCs from 4 different donors were then pooled together $(1.25 \times 105 \text{ PBMCs from each donor)}$ to 821 make up 5.0×105 cells in total. The remaining cells were used for DNA extraction (Qiagen, 69504). 822 The pooled PBMCs were resuspended in 22.5 µl of cell staining buffer (BioLegend, 420201) and 823 blocked by incubation for 10 min on ice with 2.5 µl Human TruStain FcX block (BioLegend, 422301). 824 The PBMC pool was then stained with TotalSeq-C Human Cocktail, V1.0 antibodies (BioLegend, 825 399905) according to the manufacturer's instructions (1 vial per pool). For a full list of TotalSeq-C 826 antibodies (130 abs + 7 isotype controls) refer to Extended Data Table 1j. Following a 30 min 827 incubation period with the TotalSeq-C Human Cocktail V1.0 antibodies (at 4 °C in the dark) the PBMCs 828 were topped up using cell staining buffer and centrifuged down to a pellet (500g for 5 min at 4 °C) and 829 discarding the supernatant. The pellet was then resuspended and washed in the same manner two more 830 times using the resuspension buffer (0.05% BSA in HBSS), before finally being resuspended in a 20-831 $30 \,\mu\text{L}$ resuspension buffer and counted again. The PBMC pools were then processed immediately for 832 10x 5' single cell capture (Chromium Next GEM Single Cell V(D)J Reagent Kit v1.1 with Feature 833 Barcoding technology for cell Surface Protein-Rev D protocol). 25,000 cells were loaded from each 834 pool onto a 10x chip.

835

836 PBMC Dextramer staining for SARS-CoV-2 antigen specific T cell enrichment and single-cell 837 sequencing

838 In order to further validate and investigate the SARS-CoV-2 antigen-specific T-cell populations in our 839 single cell dataset Day 10, 14 and 28 post-inoculation PBMCs samples, from all 16 participants, were 840 further enriched and processed for single cell sequencing using a multi-allele panel of 44 SARS-CoV-841 2 antigen specific dCODETM Dextramer® (10x compatible) (Immudex, see Extended Data Table 1k 842 for full panel). This panel includes; five antigen-specific T-cell populations, spanning four MHCI and 843 one MHCII alleles (covering a total of 15 participants, see Extended Data Table 11) and several 844 negative controls. Samples were then stained with several FACS antibodies (for monocyte and T cells) 845 and sorted using MACSQuant® Tyto® Cell Sorter (Miltenyi Biotec), where PE-dCODE Dextramer®-846 positive cells were collected and processed for 10x 5' single cell capture. This allowed for the 847 quantification of paired clonal TCR sequence and TCR specificity by overlaying single-cell V(D)J 848 expression onto dCODE Dextramer®-positive cell clusters.

849

850 The dextramer staining protocol was taken from Immundex and optimised/adapted to suit our samples 851 and pooling/staining strategy. In brief, the PBMC samples were thawed in batches of 7 to 8 samples 852 and the cell number and viability for each sample calculated using Trypan Blue as previously described 853 above. All cells from each sample were then pooled together in a fresh 1.5 mL eppendorf tube. Note: 854 The pooling strategy here was such that only one sample per participant/donor was used per pool in 855 order to enable de-multiplexing by genotype later on and each pool containing a mixture of timepoints 856 to help reduce batch effect. In order to ensure the collection of as many cells as possible, each of the 857 original sample tubes was then washed with 200 µl of staining buffer (1X PBS pH 7.4 containing 5% 858 Heat inactivated FBS (Thermo Fisher Scientific, 10500064) and 0.1g/l Herring sperm DNA (Thermo 859 Fisher Scientific, 15634017) and added to the pool. The tube was then topped up to 1.4 mLs with 860 staining buffer and centrifuged down to a pellet (400g for 5 min at 4 °C). The supernatant was carefully 861 removed and the cell pellet gently resuspended in a total of 30-40 µl staining buffer depending on 862 pellet's size, ready for staining.

863

In parallel the dCODETM Dextramer[®] master mix was prepared (in the dark) as per manufacturer protocol. To help avoid aggregates, each individual dextramer reagent was first microcentrifuge at full speed for 5 mins before adding 2 μL from each dCODETM Dextramer[®] specificity to a low-bind nucleus free 1.5 eppendorf tube (Eppendorf, 30108051) containing 8.8 μl 100μM d-Biotin (Avidity science, BIO200) (0.2 ul d-Biotin per number of dCODETM Dextramer[®] specificity i.e. 44).The dCODETM Dextramer[®] master mix was mixed by gently pipetting before the total volume (96.8 μl) was added to the resuspended cells. The sample was then thoroughly mixed and incubated at room temperature for

871 30 mins in the dark. Following the addition of anti-human CD14-FITC (Biolegend, 325603) and CD3-872 APC (Biolegend, 300458) (at 1:50) the cells were incubated for a further 20 mins (at room temperature 873 in the dark) before being topped up to 1.4 mL with wash buffer (1X PBS pH 7.4 containing 5 % heat 874 inactivated FBS). The cells were centrifuged down to a pellet (400g for 5 min at 4 °C) and the 875 supernatant discarded. The wash step was then repeated X2, with the latter using the addition of 1.4 mL 876 wash buffer + 1:5000 DAPI (Sigma) as live/dead stain. The supernatant was removed and the cell pellet 877 resuspended in 4 mL FACS buffer ; 1X PBS, 1% FBS, 25mM HEPES (Thermo Fisher Scientific, 878 15630-056) and 1 mM EDTA. The samples were then filtered (35 µm nylon mesh cell strainer) and PE 879 dCODE Dextramer®-positive cells sorted using a MACSQuant® Tyto® Cell Sorter as per 880 manufacturer guide (Settings; Mix speed= 800 rpm, Chamber temperature= 4 °C, Pressure= 150hPA, 881 Noise Threshold = 14.40, Trigger Threshold= off). Note: In order to collect as many cells as possible 882 during sorting the entire sample was run on the MACSQuant Tyto, with the negative run through 883 collected and re-run a second time to ensure no true positives were lost. See Extended Data Fig. 8a for 884 gating strategy for sorting. The PE dCODE Dextramer®-positive cells were then collected, centrifuged 885 (400g for 5 min at 4 °C) and resuspended in resuspension media before counting the cells. The entire 886 sample was then processed for 10x 5' single cell capture (Chromium Next GEM Single Cell V(D)J 887 Reagent Kit v1.1 with Feature Barcoding technology for cell Surface Protein-Rev D protocol). Where 888 over 25,000 cells were collected the sample was split equally and loaded over two lanes.

889

In order to provide additional controls, participants with non-compatible HLA types, including one
volunteer (674700) matching none of the HLA types for the multi-allele dCODE Dextramer panel, were
also processed and used to determine background noise.

893

894 Library generation and sequencing

895 The Chromium Next GEM Single Cell 5' V(D)J Reagent Kit (V1.1 chemistry) was used for single-cell 896 RNA-seq library construction for all nasopharyngeal swab samples, and the Chromium Next GEM 897 Single Cell V(D)J Reagent Kit v1.1 with Feature Barcoding technology for cell surface proteins was 898 used for PBMCs, both to process the PBMCs stained with CITE-sequencing antibodies panel and the 899 dCODETM Dextramer[®] (10x compatible) panel. GEX and V(D)J libraries were prepared according to 900 the manufacturer's protocol (10x Genomics) using individual Chromium i7 Sample Indices. Additional 901 TCR γ/δ enriched libraries were also generated based upon an in-house protocol previously described 902 in ³⁰. The cell surface protein libraries were created according to the manufacturer's protocol with slight 903 modifications used for the creation of libraries generated from the CITE-sequencing antibody panel. 904 These included doubling the SI primer amount per reaction and reducing the number of amplification 905 cycles to 7 during the index PCR to avoid the daisy chains effect. GEX, V(D)J and the CITE-sequencing

906 derived cell surface protein indexed libraries were pooled at a ratio of 1:0.1:0.4 and sequenced on a907 NovaSeq 6000 S4 Flowcell (paired-end, 150 bp reads) aiming for a minimum of 50,000 paired-end

- 908 reads per cell for GEX libraries and 5,000 paired-end reads per cell for V(D)J and cell surface protein
- 909 libraries. The dextramer derived cell surface protein indexed libraries were submitted at a ratio of 0.1.
- 910

911 Single cell genomics data alignment

912 Single-cell RNA-seq and CITE-seq data from PBMCs was jointly aligned against the GRCh38 913 reference that 10X Genomics provided with CellRanger 3.0.0, and alignment was performed using 914 CellRanger 4.0.0. CITE-seq antibody-derived tag (ADT) barcodes were aligned against a barcode 915 reference provided by the supplier, which we annotated to add informative protein names and made 916 available in our GitHub repository. Single-cell RNA-seq data from nasopharyngeal swab samples were 917 aligned against the same reference using STARSolo 2.7.3a, and post-processed with an implementation 918 of emptydrops extracted from CellRanger 3.0.2. To detect viral RNA in infected cells, we added 21 919 viral genomes including pre-Alpha SARS-CoV-2 (NC 045512.2) to the above mentioned reference 920 genomes for RNA-seq alignment, as described in Yoshida et al⁵. Single cell alpha/betaTCR and BCR 921 data was aligned using CellRanger 4.0.0 with the accompanying GRCh38 VDJ reference that 10X 922 Genomics provided. Single cell gamma/delta TCR data was aligned against the GRCh38 reference that 923 10X Genomics provided with CellRanger 5.0.0, using CellRanger 6.1.2.

924

925 Single cell genomics data processing

Both single cell RNA-seq and ADT-seq data were corrected using SoupX³¹ to remove free-floating and 926 927 background RNAs and ADTs. To correct ADT counts, SoupX 1.5.2 parameters soupQuantile and 928 tfidfMin parameters were set to 0.25 and 0.2, respectively, and lowered by decrements of 0.05 until the 929 contamination fraction was calculated using the autoEstCont function. SoupX on RNA data was 930 performed using default settings. To confidently annotate SARS-CoV-2 infected cells, we used SoupX 931 corrected viral RNA counts to remove false positives due to freely floating SARS-CoV-2 virions. 932 However, when quantifying the amount of reads per cell in **Fig. 2h** and their distribution over the viral 933 genome in Fig. 2f, we used the raw counts and sequencing data. To profile the distribution of viral 934 reads, we removed PCR duplicates from the aligned BAM files that STARSolo produced with 935 MarkDuplicates in picard (https://broadinstitute.github.io/picard/), and tallied the location within the 936 SARS-CoV-2 genome using the start of each sequencing read. Aligned single cell RNA-seq data was 937 imported from the *filtered feature bc matrix* folder into Seurat V4.1.0 for processing, keeping only 938 cells with at least 200 RNA features detected. Nasopharyngeal and PBMC cells with more than 50% 939 and 10% of the counts coming from mitochondrial genes were excluded, respectively. SoupX corrected

gene expression and ADT counts were normalized by dividing it by the total counts per cell andmultiplying by 10 000, followed by adding one and a natural-log transformation (log1p).

942

943 Demultiplexing and patient id assignment

944 Each PBMC sample was pooled twice into two unique pools containing up to four PBMC samples per pool, followed by CITE-seq and single cell VDJ sequencing as described above. Souporcell V2.0 32 was 945 946 used to demultiplex each pools based on the genotype differences between the mixed samples. 947 Souporcell analyses were performed with the skip remap parameter enabled and using the common 948 SNP database that was provided by the software. We used two complementary approaches to 949 confidently assign participant identity to each souporcell cluster. First we compared the cluster 950 genotypes with SNP array derived genotyping data, generated for all participants and performed using 951 the Affymetrix UK Biobank AxiomTM Array kit by Cambridge Genomic Services (CGS). Second, the 952 combinations of samples within each pool was unique, enabling assignment of participant identity based 953 on the presence of unique participant-specific combinations of identical genotypes in two separate 954 pools. This multiplexing and replication strategy furthermore enabled us to distinguish library specific 955 batch effects from participant specific effects in downstream analyses.

956

957 Doublet detection

We used the output from souporcell to identify ground-truth doublets in PBMCs by selecting droplets that contained two genotypes from different participants. We then included these ground-truth doublets into the iterative rounds of subclustering and cell state annotation to look for doublet specific clusters that emerged, which we then subsequently removed. Doublets in the nasopharyngeal data were removed during iterative rounds of subclustering and cell state annotation by identifying cell clusters that expressed marker genes from multiple distinct cell types.

964

965 Clustering and cell type annotation

966 Principal component analysis was run on corrected gene expression counts from selected hypervariable 967 genes and the first 30 principal components were selected to construct a nearest neighbour graph and UMAP embedding. We used harmony³³ to perform batch correction on the PBMC data on the 968 969 sequencing library identity to remove technical batch effects. Leiden clustering³⁴ performed at 970 resolutions of 0.5, 1, 4 and 32, on nearest neighbour graphs and embeddings created with 500, 1000, 971 2000, 4000, 6000 and 8000 selected hypervariable genes (excluding TCR and BCR genes), was used to 972 perform iterative rounds of cell type annotation based on marker gene expression and subsetting of 973 clusters to obtain a highly granular cell state annotation. We used cell type marker genes described in

974 Yoshida et al⁵ and Stephenson et al⁴ to define cell types. Our cell type annotation was furthermore
975 guided by predicted cell type labels using Celltypist's³⁵ provided models and custom trained models
976 based on annotations in Yoshida et al⁵ and Stephenson et al⁴.

977

978 Single cell TCR and BCR data processing

979 Aligned single cell BCR and alpha/beta TCR sequencing data was imported in scirpy³⁶ to obtain a cell

by TCR or BCR formatted table, which was then added to Seurat objects containing gene expression

981 data. Aligned single cell gamma/delta TCR data was reannotated using Dandelion V0.2.4³⁷.

982

983 Integration of five COVID-19 studies

All transcriptomic data was processed with the single cell analysis Python workflow Scanpy³⁸. Each 984 985 data set was individually filtered following best practices outlined in³⁹ (Between 200 and 3500 genes 986 per cell, less than 10% mitochondrial genes expressed per cell, genes expressed in at least 3 cells, other 987 parameters at default). The gene sets were reduced to their intersection before combining data sets. Cells 988 came from a total of 602 individuals, with 325 acute COVID-19 patients, 110 COVID-19 convalescent 989 patients, 114 healthy and 53 hospitalized controls (Extended Data Table 1d). This resulted in an 990 integrated embedding containing 946,584 T cells with resolved TCR from 494 samples, made up of 455 991 donors of which 240 were acute COVID-19 patients, 82 convalescent, 88 healthy and 45 hospitalized 992 controls (Extended Data Table 1e). The total number of donors in the integrated object is smaller as 993 only samples with matching VDJ sequencing data were kept. A probabilistic scVI model (2 hidden 994 layers, 128 hidden nodes, 20-dimensional latent space, negative binomial gene likelihood, other 995 parameters at default⁴⁰) was trained on the data to map cells to a shared latent space, and visualised 996 using UMAP.

997

998 Identification of activated TCR clonotype groups using Cell2TCR

999 To identify TCR clonotype groups, we used tcrdist3⁴¹ with the provided human references to compute 1000 a sparse representation of the distance matrices for all identified TRA and TRB CDR3 sequences, with 1001 the radius parameter set to 150. We then summed the distances for TRA and TRB to obtain a combined 1002 distance matrix. Next, we iterated over possible TCR distance thresholds between 5 and 150 with 1003 increments of 5, to compute TCR clonotype groups at each threshold. We then generated a distance adjacency graph of TCRs from different T cells with a distance lower than the threshold, which was 1004 clustered to identify TCR clonotype groups using leiden³⁴ clustering through the igraph package⁴², at a 1005 resolution of 1 and using the RBConfigurationVertexPartition partition. To find the optimal distance 1006 1007 threshold at which only TCRs that recognise the same antigen are grouped together, we quantified

1008 clonotype group contamination at each threshold using two approaches. First, we assumed that T cells 1009 that were annotated as naive should not participate in an expanded clonotype group, and quantified the 1010 proportion of naive T cells in each clonotype group to determine the largest threshold at which we 1011 observed minimal participation of naive T cells. Second, we assumed that CD4+ T cells and CD8+ T 1012 cells should never be part of the same TCR clonotype group, so we set out to quantify the proportion of 1013 CD4+/CD8+ mixing in each clonotype group to find the largest threshold where mixing is minimal. 1014 Both approaches revealed the same optimal threshold of 35 at which both naive T cell participation and 1015 CD4+/CD8+ mixing is minimal, which we then used for downstream analyses. To identify activated 1016 TCR clonotype groups we assumed that these groups should include activated T cells and that we should 1017 at least detect multiple independent TCR clonotypes that appear to be raised against the same antigen 1018 at the same time; we therefore selected clonotype groups that contained at least one participating 1019 activated T cell and that contained at least two unique CDR3 nucleotide sequences.

1020

1021 Identification of activated BCR clonotype groups

1022 To identify BCR clonotypes groups that were activated during infection, we used a similar approach as 1023 described above for T cells. Instead of using tcrdist to compute distances, we used the levenshtein 1024 distance and iterated over possible thresholds between 1 and 20 to find an optimal threshold by 1025 quantifying naive B cell participation. This revealed that a levenshtein distance of 2 is optimal to 1026 identify BCR clonotype groups that only contain B cells that recognise the same antigen. To identify 1027 activated BCR clonotype groups, we assumed that these groups should include antibody secreting B 1028 cells (plasmablasts and plasma cells) and that we should at least detect multiple independent BCRs 1029 clonotypes that appear to be raised against the same antigen at the same time; we therefore selected 1030 clonotype groups that contained at least one participating antibody secreting B cell and that contained 1031 at least three unique CDR3 nucleotide sequences.

1032

1033 Generation of VDJ logos

1034 TCR and BCR logos in Figure X, X and X were generated by providing the CDR3 amino acid sequences
1035 of each clonotype group to the ggseqlogo R package⁴³ or the logomaker Python package⁴⁴. When
1036 clonotype groups contained CDR3 amino acid sequences of variable lengths, we selected the sequences
1037 with the most frequently occurring length within each group for visualization purposes only.

1038

1039 Generalized linear mixed models of cell state compositional changes over time

1040 The relative amount of cells per cell type in each sample was modeled using a generalized linear mixed 1041 model with a poisson outcome. When technical replicates were available (most of the PBMC samples),

1042 these were modeled as separate samples. We modeled participant identifiers, days since inoculation, 1043 and sequencing library identifiers (of multiplexed libraries), as random effects terms to overcome 1044 colinearity between these factors. The effect of each clinical/technical factor on cell type composition 1045 was estimated by the interaction term with the cell type. The glmer function in the lme4 package 1046 implemented on R was used to fit the model. The standard error of the variance parameter for each 1047 factor was estimated using the numDeriv package. The conditional distribution of the fold change 1048 estimate of a level of each factor was obtained using the ranef function in the lme4 package. The log-1049 transformed fold change is relative to the pre-inoculation time point (day -1). The statistical significance 1050 of the fold change estimate was measured by the local true sign rate, which is the probability that the 1051 estimated direction of the effect is true, that is, the probability that the true log-transformed fold change 1052 is greater than 0 if the estimated mean is positive (or less than 0 if the estimated mean is negative). We 1053 calculated P values using a two-sample Z-test using the estimated mean and standard deviation of the 1054 distribution of the effect (log-transformed fold change). P values were converted into false discovery 1055 rates using the Benjamini & Hochberg method.

1056

1057 Gaussian processes regression and latent variable models to infer time since viral exposure

1058 To infer time from cell state abundances, we first generated a linear regression model using CellTypist 1059 to predict PBMC or nasopharyngeal cell states based on the highly detailed manual cell state annotation 1060 presented in this work. Celltypist models were trained and used using default parameters, with 1061 check expression set to false, balance cell type set to true, feature selection set to true, and max iter 1062 set to 150. We next set out to build a predictive model to infer time since viral exposure using the PBMC 1063 data presented in this work as a training dataset. We used the above mentioned publicly available PBMC 1064 data from five studies as a test dataset to predict time since viral exposure on. Because we were 1065 specifically interested in comparing time since viral exposure to reported time since onset of symptoms 1066 in varying disease severities, we excluded samples for which these features were unknown. To ensure 1067 that the cell state proportions in the training and test dataset were similar, we used our CellTypist model 1068 on both datasets to predict relative cell state frequencies, which was used as input for our time prediction 1069 model. To account for participant-to-participant heterogeneity and continuous variation in the timeline 1070 of immune responses, we first constructed a gaussian process latent variable model ⁴⁵ (GPLVM) to 1071 smooth the time since viral exposure in the training dataset. We applied the Pyro implementation of 1072 GPLVM ⁴⁶ across all predicted cell state abundances, and restricted the model to 2000 iterations and a 1073 single latent variable that was initialized on the square root transformed time since inoculation, which 1074 resulted in an accurate recapitulation of the mean time since inoculation while smoothing outliers. We 1075 next used each predicted cell state as input for a task to generate a multi-task gaussian process regression 1076 model⁴⁷ to predict the smoothened time since inoculation using GPvTorch⁴⁸. We used the Adam 1077 optimiser and allowed for as many iterations for the loss in marginal log likelihood to reach zero. We

next predicted the cell state compositions across the entire tested timeline (day -1 to day 28), and
compared these cell state compositions to the cell state compositions in our query dataset as predicted
by our CellTypist model. Last, we selected the time point whose predicted cell state composition had
the lowest mean squared error compared to the observed cell state composition.

1082

1083 Matching clonotype groups to antigen-TCR database

1084 Computation of fold change enrichment of SARS-CoV-2 specific TCRs in Activated T cell populations 1085 compared to other T cell populations: Median p for 10 random draws of n=5000 unique clones of both 1086 populations = 3.75, p = 1.68×10^{-21}

1087

1088 Bulk TCR sequencing and processing

1089 Total RNA was extracted from whole blood samples collected in Tempus Blood RNA tubes 1090 (Thermofisher #4342792) using the manufacturer's protocol for RNA extraction. TCR α and β genes 1091 were sequenced using a pipeline which introduces unique molecular identifiers attached to individual 1092 cDNA molecules using single-stranded DNA ligation. The unique molecular identifier allows 1093 correction for sequencing error PCR bias, and provides a quantitative and reproducible method of repertoire analysis. Full details for both the experimental TCRseq library preparation (49,50) and the 1094 subsequent TCR annotation (V, J and CDR3 annotation) using Decombinator V4⁵¹ are published. The 1095 1096 Decombinator software is freely available at https://github.com/innate2adaptive/Decombinator.

1097

1098 Memory formation analysis

T cell phenotypes (naive, activated, effector, memory) were recorded for an antigen-specific TCR clone at different time points throughout infection. TCR clones were filtered by having an activated label at least once, being observed in at least two samples, one of which had to be at day 28. Unique TCR clones are distinguished by color and numbered with their clone_id identifier. A shaded area is drawn when the same clone appeared with several distinct cell type labels, and the size of the shaded area informs of their relative ratios.

1105

1106 Quantifying TCR diversity restriction in phenotypic clusters using coincidence analysis

1107 To quantify the diversity of TCRs found within different phenotypic clusters we determined the 1108 probability with which two distinct clonotypes within a cluster share an identical CDR3 amino acid 1109 sequence ⁵². For visualization we normalized these probabilities by the same quantity calculated over 1110 the complete data regardless of phenotype. This ratio of probability of coincidences provides a stringent

- 1111 measure of convergent functional selection of distinct clonotypes that share the same TCR. The analysis
- 1112 is based on clonotypes defined by distinct nucleotide sequences of the hypervariable regions, and does
- 1113 not make direct use of clonal abundances as these can also reflect TCR-independent lineage differences.
- 1114 We focused our analysis on conventional T cells only, considered only cells with at least one valid
- 1115 functional alpha and beta chain, and kept only a single chain for each cell where there were multiple
- 1116 chains. We performed the analysis both on the alpha and beta chain separately, as well as on paired
- alpha and beta chain, in each instance requiring exact matching of the CDR3 amino acid sequences.

1119 Figure Legends

1120

1121 Figure 1: Extensive temporal cell state dynamics after SARS-CoV-2 inoculation.

1122 (a) Illustration of study design and cohort composition. (b-c) UMAPs of all nasopharyngeal cells, color-1123 coded by their broad cell type annotation in (b), by the infection group in the top panel of (c), and by 1124 days since inoculation in the bottom panel of (c). Only cells from sustained infection cases are shown 1125 in the bottom panel of (c). (d-e) UMAPs as in (b-c), but showing all PBMCs. (f) Fold changes in 1126 abundance of nasopharynx resident broad immune cell type categories. Immune cell abundances were 1127 scaled to the total amount of detected epithelial cells in every sample prior to calculating the fold 1128 changes over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled 1129 abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap 1130 right of the dotplot to aid the interpretation of changes in cell type abundances.

1131

1132 Figure 2: Cell-state-specific antiviral responses and infection

1133 (a) Dotplot visualizing the mean expression of interferon stimulated genes across cell types and time 1134 since inoculation in participants with sustained infections, for nasopharyngeal cells (left plot) and 1135 PBMCs (right plot). (b) Dotplot as in (Fig 1f), showing myeloid cell types in sustained infection cases 1136 that significantly change at least one time point compared to pre-infection. Nasopharyngeal cells and 1137 PBMCs are shown in the left and right plot, respectively. (c) Boxplot showing the relative amounts of 1138 circulating inflammatory monocytes over time since inoculation in each infection group. (d) Boxplot 1139 showing the fraction of circulating MAIT cells that are activated over time since inoculation in each 1140 infection group. (e) Stacked barplot showing the amount of nasopharyngeal cells with at least one 1141 SARS-CoV-2 RNA read detected (after background subtraction), split by days since inoculation and 1142 color-coded by cell type. (f) Barplots showing the distribution of detected viral reads over the SARS-1143 CoV-2 genome in the five most highly infected cell types. The blue line represents a loess fit over the 1144 data. The top-right inset illustration is shown to aid the interpretation of a uniform read distribution 1145 versus a 3' biased read distribution. (g) Boxplot showing the fraction of ciliated cells that are annotated 1146 into detailed response or infection cell states. Only cells from sustained infection cases are shown and 1147 split by days since inoculation. The Y axis for interferon (IFN) and acute-phase response (APR) positive 1148 ciliated cells is shown on the left, while the Y axis for infected ciliated cells is shown on the right. (h) 1149 Boxplot of the amount of viral sequencing reads per cell type. (i) Heatmap of spearman correlations 1150 between host gene expression and the amount of viral reads found in each cell, split by cell type. Shown 1151 genes correlate the highest with gene expression in ciliated cells. In all box plots, the central line and 1152 the notch are the median and its approximate 95% confidence interval, the box shows the interquartile 1153 range and the whiskers are extreme values upon removing outliers.

1154

1155 Figure 3: Adaptive immune responses emerge at day 10 post-inoculation.

1156 (a) UMAP of all circulating T cells, highlighting the distinct cluster of activated T cells. Cells are color 1157 coded and labeled by their detailed cell state annotation. (b) Marker gene and protein expression of 1158 activated T cell subsets are shown in blue and red, respectively. (c) Percentages of nasopharyngeal T 1159 cells that were annotated as activated T cells, split over days since inoculation and color coded by 1160 infection group. (d) Boxplot as in (c), but showing circulating activated T cells. (e) UMAP as in (a), but 1161 showing nasopharyngeal T cells. (f) Fold changes in cell state abundance compared to pre-inoculation 1162 of nasopharyngeal and circulating conventional T cells are shown in the left and right plots, respectively. 1163 Only cell states that significantly change at a FDR < 10% at least one time point are shown. 1164 Nasopharyngeal T cell abundances were scaled to the total amount of detected epithelial cells. Fold 1165 changes and significance were calculated by fitting a GLMM as shown in *Figure 1*. The mean cell type 1166 proportions over all cells and samples is shown in the green heatmap right of the dotplot to aid the 1167 interpretation of changes in cell type abundances. (g) TCR clonality and expansion at day 14 of activated 1168 TCRs was validated using bulk TCR sequencing. For TCRs that matched the single cell gene 1169 expression, normalized clonality TCR alpha (left) and beta (right) data is separated by type and 1170 expressed as the average fraction of total clones in sample contributed by a cell of that type, with 1171 changes over time implying clonal expansion or contraction. For activated T cell types of interest, 1172 scatterplots for each sustained infection and at each time point sampled (days -1, 7, 14) are drawn. (h) 1173 Proportion of CD8+ infiltrating T cells that use alpha/beta TCRs, typical Dv2/Gv9 g/d TCRs, or atypical 1174 g/d TCRs is shown. (i) The relative immune repertoire composition of g/d T cells in circulation and 1175 nasopharynx after challenge are shown in the left and right bars, respectively. G/d chain pairs that are 1176 significantly more or less abundant between circulation and nasopharynx (p < 0.05) are highlighted with 1177 an asterisks. (i) Dotplot as in (f), showing the fold changes in B cells. Legend for significance and mean 1178 cell type proportions as in (f). (k) Abundance of TCR clusters relative to all TCRs are shown over time 1179 since inoculation. Activated TCR clusters are color coded and their TCR motifs are shown. Legend for 1180 the physicochemical properties of amino acids in shown TCR motifs is shown in panel (1). (1) Plot as in 1181 (k), but showing BCR clusters. Immunoglobulin class usage within each activated BCR cluster is shown 1182 in the rightmost bars.

1183

1184 Figure 4: Integrating COVID-19 patient data reveals public SARS-CoV-2 TCR motifs

1185 (a) UMAP representation after integration of five COVID-19 patient datasets with paired RNA and

1186 VDJ sequencing data. Cell type labels inferred using a logistic regression classifier (Celltypist) trained

- 1187 on manual annotations of PBMCs from the current work. (b) Fraction of activated T cells across all T
- 1188 cells in sample for COVID-19 (n = 240), convalescent (n = 82) and healthy (n = 88) samples of five

1189 COVID-19 patient datasets. Significance levels after Mann-Whitney testing are shown and indicate that 1190 COVID-19 and convalescent samples have significantly more activated T cells than healthy samples. 1191 (c) Activated T cell types highlighted on UMAP representation from panel (a). Activated CD8+ T cells 1192 were most abundant, followed by CD4+ and regulatory types, and clustered together in a distinct area 1193 of the latent space. (d) Clustermap of pairwise TCR distances with color-coded information for each 1194 TCR on patient id, study, motif, antigen on the left-hand side, as well as the sequence logos for the nine 1195 most common motifs on the right-hand side. Each column/row corresponds to a unique TCR, and the 1196 distance to each TCR in the set is indicated by color. Only activated T cells with public motifs (identified 1197 in more than one individual) were considered. Low distances indicate similar TCRs, with distances of 1198 40 and less potentially vielding TCRs recognising the same epitopes. For sequence logos, letter height 1199 indicates frequency of AA at that position across T cells pertaining to the motif. AAs are colored by 1200 side chain chemistry: Acidic (red), basic (blue), hydrophobic (black), neutral (purple), polar (green). 1201 AA: amino acid. (e) Recorded symptoms averaged over SARS-CoV-2 challenge participants with 1202 sustained infection for days -1 to 14 post-inoculation. Major molecular events in the immune response 1203 are highlighted with arrows. (f) Predicted time since viral exposure is plotted against reported time since 1204 onset of symptoms. Lines represent loess fits of the data split and color coded by reported severity.

1205

1206 Figure 5: Temporally resolved epithelial and immune response in SARS-CoV-2 infections

Summary figure highlighting 1) temporal differences in the distinct infection groups, 2) novel antiviral
responses, 3) novel characteristics of sustained infection, and 4) the identification of public motifs in
SARS-CoV-2 specific activated T cells. In addition, our work provides community tools for inference
of specific TCR motifs (Cell2TCR) in activated T cells, and for temporal assignments of clinical
COVID-19 samples underpinning future therapeutic applications.

1212

1213 Supplementary Figure 1: Overview of Single Cell Human SARS-CoV-2 Challenge Study cohort.

1214 (a) Timeline of the samples collected from each of the 16 participants enrolled in our study. Sample 1215 collections are shown relative to the date of SARS-CoV-2 inoculation (day 0). Samples are shown by 1216 infection group (sustained, transient and abortive), with their age in years (yrs) and sex (self-identified). 1217 *Indicates participants who were either vaccinated (636163) or reported to have developed an 1218 community infection, before or immediately after blood samples were taken on day 28 (677696 and 1219 677306). See sample collection section in the methods for more details. Longitudinal measures of nasal 1220 and pharyngeal (throat) viral kinetics from swabs. Shown for each participant as measured via (b) RT-1221 qPCR and (c) quantitative culture by focus forming assay (FFA). Patients were identified as testing 1222 positive if they had at least one RT-qPCR test where the viral load was able to be quantified (≥lower 1223 limit of quantification (LLOQ)). Six participants were seen to present multiple, sequential, positive RT-

1224 qPCR results and were classified as having a sustained infection. Three participants were seen to have 1225 standalone positive results and were classified having transient infections. Seven participants never 1226 presented a single RT-qPCR test result \geq LLOQ and these were classified as abortive infections. FFA 1227 tests were only performed for patients identified as having sustained infections, so there is no data for 1228 participants with transient or abortive infections. Infection intervals for each participant were calculated 1229 based on the first and last across the nose and throat, where positive tests below the LLOQ were counted 1230 if they occurred < 2 days of a quantifiable (\geq LLOQ) test result. *Indicated where the patient was 1231 discharged from quarantine prior to testing negative. The black octagon highlights patients that were 1232 still reporting positive results at day 28 post-inoculation.

1233

1234 Supplementary Figure 2: All identified and annotated cells.

(a) UMAP of all PBMCs, color-coded and labeled by detailed cell state annotation. Subsets of B cells
with differential immunoglobulin chain usage are not shown in full detail for clarity. (b) UMAP of all

- 1237 nasopharyngeal cells, color-coded and labeled by detailed cell state annotation.
- 1238

1239 Supplementary Figure 3: Marker gene expression used for annotation.

- 1240 Marker gene expression of cell states annotated in (a) nasopharyngeal immune cells, (b)
- 1241 nasopharyngeal epithelial cells, (c) myeloid and progenitor PBMCs.
- 1242

1243 Supplementary Figure 4: Marker gene expression used for annotation of PBMCs.

- Marker gene expression of cell states annotated in (a) T, NK and ILC cells in PBMCs, (b) B cells inPBMCs.
- 1246

1247 Supplementary Figure 5: Quality control metrics of single cell RNA-seq data.

- 1248 Calculate quality control metrics for nasopharyngeal swabs showing (a) cells per sample and (b) gene 1249 reads per cell per sample. (c) and (d) show the same respectively for PBMCs.
- 1249 Teads per cent per sample. (c) and (d) show the same respectively ic
- 1250

1251 Supplementary Figure 6: Temporal response states and activated T cells.

(a) Line plot showing the mean proportions of interferon stimulated cells over time since inoculation
within cell types with a distinct and annotated cluster of interferon stimulated cells. (b) Marker gene
expression of activated MAIT cells. (c) Marker gene expression of response states observed in ciliated

1255 cells. (d) TCR repertoire overlap of nasopharyngeal and circulating conventional T cells. We only

1256 considered the beta TCR chain to identify overlapping T cells to include T cells without a TRA sequence 1257 detected. (e) Memory analysis in an individual with sustained SARS-CoV-2 infection. Unique TCR 1258 clones are distinguished by color and numbered with their clone id identifier. A shaded area is drawn 1259 when the same clone appeared with several distinct cell type labels, and the size of the shaded area 1260 informs their relative ratios. (f) TCR bulk data with matched single cell labels as in Fig. 3g, but showing 1261 data on abortive infections for activated and other T cells. No particular changes are observed across 1262 the three time points sampled. (g) The fraction of activated T cells that participate in TCR clonotype 1263 groups versus the fraction of cells in each group that originate from participants with sustained 1264 infections. (h) Scatterplot as in (g), but showing BCR clonotype groups and the fraction of antibody 1265 secreting B cells instead of activated T cells. (i) Fraction of unique clones matching SARS-CoV-2 1266 entries in IEDB across all T cell clones within that broad T cell compartment. Significance level after 1267 Whitney-Mann testing shown for Activated vs Memory T cells (putative SARS-CoV-2 fraction 3.75 times higher in Activated T cells, p = 1.68 * 10-21 (j) Difference between predicted time since viral 1268 1269 exposure and reported time since onset of symptoms, split by reported severity. In all box plots, the 1270 central line and the notch are the median and its approximate 95% confidence interval, the box shows 1271 the interquartile range and the whiskers are extreme values upon removing outliers (k) Coincidence 1272 analysis of TCR sequence diversity restriction in phenotypic subsets. Fraction of clonotype pairs within 1273 each phenotypic cluster that share identical CDR3 amino acid sequences (but distinct nucleotide 1274 sequences) normalized by the same statistics calculated across all clonotypes, for alpha, beta, and both 1275 chains together. The ratio of within cluster versus overall sequence coincidence probabilities is a measure of the breadth of epitopes targeted by the different clonotypes within a cluster ⁵². 1276

1277

1278 Supplementary Figure 7: Detailed temporal dynamics in cell state abundances.

1279 (a) Fold changes in abundance of cell states in PBMCs. Detailed annotation of interferon stimulated 1280 subsets and immunoglobulin class specific cell states are not shown for clarity. Immune cell abundances 1281 were scaled to the total amount of detected PBMCs in every sample prior to calculating the fold changes 1282 over days since inoculation compared to pre-infection (day -1) by fitting a GLMM on scaled 1283 abundances. The mean cell type proportions over all cells and samples is shown in the green heatmap 1284 right of the dotplot to aid the interpretation of changes in cell type abundances. (b) Dotplot as in (a), 1285 but showing nasopharyngeal immune cells. Immune cell abundances were scaled to the total amount of 1286 detected epithelial cells in every sample. (c) Dotplot as in (a), but showing nasopharyngeal epithelial 1287 cells. (d) UMAP of all CD8+ T cells from the Dextramer assay, with cell types predicted by Celltypist 1288 model trained on previous PBMC data. Activated T cells form a distinct cluster. (e) Cell counts for 1289 CD8+ T cell types by HLA compatibility of donor with the highest-bound Dextramer. Only Activated 1290 T cells have positive log2 fold change for HLA-matched Dextramers. (f) UMAP as in (d), colored by 1291 HLA compatibility.

1292

1293 Supplementary Figure 8: Validation of antigen-specific activated T cells.

1294 (a) Gating strategy used to enrich SARS-CoV-2 antigen specific T cells via MACSQuant Tyto cell 1295 sorting. Cells were sequentially stained with a multi-allele panel of dCODE dextramer- PE complexes, 1296 with the addition of anti-human CD3-APC and CD14-FITC FACS antibodies as references to help us 1297 identify T cell specific binding. Debris and cell aggregates were gated out first using BSB-H 1298 (backscatter blue laser-height) SSC-H (side scatter-height). From the cells, DAPI+ dead cells were 1299 excluded. T cells (CD3+) and monocytes (CD14+) were then gated for (CD3+ and\or CD14+ 1300 population) and the sort gate defined from this population as all PE-dCODE Dextramer® positive cells. 1301 This lenient sorting strategy was decided upon in order to collect enough cells for 10X 5' single cell 1302 analysis downstream and to ensure we were capturing all SARS-CoV-2 antigen specific cells. Any non-1303 specific binding (e.g. to monocytes) and background noise could then be removed computationally. (b) 1304 Calculated quality control metrics for PE-dCODE Dextramer® positive sequenced cells showing gene 1305 reads per cell per sample. (c) Proportions of activated T cells bound to Dextramers loaded with selected 1306 SARS-CoV-2 antigens. The total amount of bound cells to each Dextramer is shown, color-coded by 1307 predicted cell state. If barcodes from several Dextramers were detected to be bound to the same cell, 1308 we only selected the Dextramer with the highest signal as bound. As a control to separate background 1309 and real binding, cells are separated based on the HLA haplotype compatibility with the tested 1310 Dextramer. Only Dextramers with at least 10 HLA matched bound cells are shown. FDR corrected p values were determined by a Fisher-exact test comparing the proportion of HLA matched activated T 1311 1312 cells in the Dextramer bound cells to the proportion of unbound HLA matched activated T cells. N 1313 represents the number of cells in each bar. The right-most bar represents the overall distribution of cell 1314 types across all Dextramer experiments.


1315 References

1316 1. Blanco-Melo, D. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of 1317 COVID-19. Cell 181, 1036-1045.e9 (2020). 1318 2. Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe 1319 COVID-19 patients. Science 369, 718-724 (2020). 1320 3. Schulte-Schrepping, J. et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell 1321 Compartment. Cell 182, 1419-1440.e23 (2020). 1322 4. Stephenson, E. et al. Single-cell multi-omics analysis of the immune response in COVID-19. 1323 Nat. Med. 27, 904–916 (2021). 1324 5. Yoshida, M. et al. Local and systemic responses to SARS-CoV-2 infection in children and 1325 adults. Nature 602, 321-327 (2022). 1326 6. Killingley, B. et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge 1327 in young adults. Nat. Med. 28, 1031-1041 (2022). Fears, A. C. et al. The dynamics of yo T cell responses in nonhuman primates during SARS-1328 7. 1329 CoV-2 infection. Commun Biol 5, 1380 (2022). 1330 Frere, J. J. et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique 8. 1331 systemic perturbations after recovery. Sci. Transl. Med. 14, eabg3059 (2022). 1332 Hinks, T. S. C. & Zhang, X.-W. MAIT Cell Activation and Functions. Frontiers in Immunology 9. 1333 vol. 11 Preprint at https://doi.org/10.3389/fimmu.2020.01014 (2020). 1334 10. Kim, D. et al. The Architecture of SARS-CoV-2 Transcriptome. Cell 181, 914–921.e10 (2020). 1335 11. Trizzino, M. et al. EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. 1336 Science Advances vol. 7 Preprint at https://doi.org/10.1126/sciadv.aaz8836 (2021). 1337 12. Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 1338 (2002).1339 13. Luan, H. H. et al. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. 1340 Cell 178, 1231–1244.e11 (2019). 1341 14. Shang, Y. et al. The transcriptional repressor Hes1 attenuates inflammation by regulating 1342 transcription elongation. Nat. Immunol. 17, 930-937 (2016). 1343 15. Wang, T. et al. PER1 prevents excessive innate immune response during endotoxin-induced liver 1344 injury through regulation of macrophage recruitment in mice. Cell Death Dis. 7, e2176-e2176 1345 (2016).

- 1346 16. Liu, L., Jiang, Y. & Steinle, J. J. TNFAIP3 is anti-inflammatory in the retinal vasculature. *Mol.*1347 *Vis.* 28, 124–129 (2022).
- 1348 17. Scholtysek, C., Uderhardt, S., Schett, G. & Krönke, G. NR4A1 modulates the inflammatory
 1349 response during murine experimental arthritis. *Ann. Rheum. Dis.* 69, 37–37 (2010).
- 1350 18. Wosen, J. E., Mukhopadhyay, D., Macaubas, C. & Mellins, E. D. Epithelial MHC Class II
 1351 Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts.
 1352 *Front. Immunol.* 9, 2144 (2018).
- 1353 19. Madissoon, E. *et al.* A spatially resolved atlas of the human lung characterizes a gland-associated
 1354 immune niche. *Nat. Genet.* 55, 66–77 (2023).
- 1355 20. Kaneko, N. *et al.* Temporal changes in T cell subsets and expansion of cytotoxic CD4 T cells in
 1356 the lungs in severe COVID-19. *Clinical Immunology* vol. 237 108991 Preprint at
 1357 https://doi.org/10.1016/j.clim.2022.108991 (2022).
- 1358 21. Meckiff, B. J. *et al.* Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells
 1359 in COVID-19. *Cell* 183, 1340–1353.e16 (2020).
- 1360 22. Wilkinson, T. M. *et al.* Preexisting influenza-specific CD4+ T cells correlate with disease
 1361 protection against influenza challenge in humans. *Nat. Med.* 18, 274–280 (2012).
- 1362 23. Phad, G. E. *et al.* Clonal structure, stability and dynamics of human memory B cells and
 1363 circulating plasmablasts. *Nat. Immunol.* 23, 1–10 (2022).
- 1364 24. Fink, K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections. *Front.*1365 *Immunol.* 3, 78 (2012).
- 1366 25. Dan, J. M. *et al.* A Cytokine-Independent Approach To Identify Antigen-Specific Human
 1367 Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. *J.*1368 *Immunol.* 197, 983–993 (2016).
- 1369 26. Altman, J. D. *et al.* Phenotypic analysis of antigen-specific T lymphocytes. *Science* 274, 94–96
 1370 (1996).
- 1371 27. Website. Coronavirus Clinical Characterisation Consortium. Site set-up. ISARIC 4C
 1372 https://isaric4c.net/protocols.
- 1373 28. Tang, Y. *et al.* Human nasopharyngeal swab processing for viable single-cell suspension v1.
 1374 *protocols.io* (2020) doi:10.17504/protocols.io.bjhkkj4w.
- 1375 29. Ziegler, C. G. K. *et al.* Impaired local intrinsic immunity to SARS-CoV-2 infection in severe
 1376 COVID-19. *Cell* 184, 4713–4733.e22 (2021).
- 1377 30. Suo, C. *et al.* Mapping the developing human immune system across organs. *Science* 376,


- 1378 eabo0510 (2022).
- 1379 31. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based
 1380 single-cell RNA sequencing data. *Gigascience* 9, (2020).
- 1381 32. Heaton, H. *et al.* Souporcell: robust clustering of single-cell RNA-seq data by genotype without
 reference genotypes. *Nat. Methods* 17, 615–620 (2020).
- 1383 33. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony.
 1384 *Nat. Methods* 16, 1289–1296 (2019).
- 1385 34. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well1386 connected communities. *Sci. Rep.* 9, 5233 (2019).
- 1387 35. Domínguez Conde, C. *et al.* Cross-tissue immune cell analysis reveals tissue-specific features in
 humans. *Science* 376, eabl5197 (2022).
- 1389 36. Sturm, G. *et al.* Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-sequencing
 1390 data. *Bioinformatics* 36, 4817–4818 (2020).
- 1391 37. Suo, C. *et al. Dandelion*utilizes single cell adaptive immune receptor repertoire to explore
 1392 lymphocyte developmental origins. *bioRxiv* (2022) doi:10.1101/2022.11.18.517068.
- 1393 38. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data
 1394 analysis. *Genome Biol.* 19, 15 (2018).
- 1395 39. Luecken, M. D. & Theis, F. J. Current best practices in single-cell RNA-seq analysis: a tutorial.
 1396 *Mol. Syst. Biol.* 15, e8746 (2019).
- 40. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling for
 single-cell transcriptomics. *Nature Methods* vol. 15 1053–1058 Preprint at
 https://doi.org/10.1038/s41592-018-0229-2 (2018).
- 1400 41. Mayer-Blackwell, K. *et al.* TCR meta-clonotypes for biomarker discovery with enabled
 1401 identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs. *Elife* 10, (2021).
- 1402 42. Csárdi, G. *et al. igraph*. (Zenodo, 2023). doi:10.5281/ZENODO.3630268.
- 43. Wagih, O. ggseqlogo: a versatile R package for drawing sequence logos. *Bioinformatics* 33, 3645–3647 (2017).
- 1405 44. Tareen, A. & Kinney, J. B. Logomaker: beautiful sequence logos in Python. *Bioinformatics* 36, 2272–2274 (2020).
- 1407 45. Bayesian Gaussian Process Latent Variable Model. *Paperpile*1408 https://paperpile.com/app/p/78b378bb-4100-016d-ac7d-6ebbb9b5f9c2.
- 1409 46. Bingham, E. *et al.* Pyro: Deep universal probabilistic programming. (2018)


1410		doi:10.48550/ARXIV.1810.09538.
1411 1412	47.	Multi-task Gaussian Process Prediction. <i>Paperpile</i> https://paperpile.com/app/p/8ade8ba1-9869-09eb-9355-5a8e00b75e2c.
1413 1414 1415	48.	Gardner, J. R., Pleiss, G., Bindel, D., Weinberger, K. Q. & Wilson, A. G. GPyTorch: Blackbox Matrix-matrix Gaussian process inference with GPU acceleration. (2018) doi:10.48550/ARXIV.1809.11165.
1416 1417 1418	49.	Uddin, I. <i>et al.</i> An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. <i>Methods in Molecular Biology</i> 15–42 Preprint at https://doi.org/10.1007/978-1-4939-8885-3_2 (2019).
1419 1420 1421	50.	Oakes, T. <i>et al.</i> Quantitative Characterization of the T Cell Receptor Repertoire of Naïve and Memory Subsets Using an Integrated Experimental and Computational Pipeline Which Is Robust, Economical, and Versatile. <i>Front. Immunol.</i> 8 , 1267 (2017).
1422 1423 1424	51.	Peacock, T., Heather, J. M., Ronel, T. & Chain, B. Decombinator V4: an improved AIRR compliant-software package for T-cell receptor sequence annotation? <i>Bioinformatics</i> 37 , 876–878 (2021).
1425 1426	52.	Mayer, A. & Callan, C. G., Jr. Measures of epitope binding degeneracy from T cell receptor repertoires. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 120 , e2213264120 (2023).



b

Viral kinetics measured by RT-qPCR








С






Extended Data Figure 1

0.5

0.5


0.5




Ionocyte IFN stim SARS-CoV-2+


Extended Data Figure 2

Mast
















b


B Naive FIN stim (GHD B Switched Memory (FIN stim (GHD B Switched Memory (GHD) B Switched Memor	,			
B Naive IFN stim (GHD B Naive IFN stim (GHD B Naive IGHD B Non-Switched Memory IGH B Switched FCRL3: IGHA B Switched Memory I				
B Naive IGN stim (CHM) B Naive IGHM B Naive IGHM B Non-Switched FCRL3; IGHD B Non-Switched Memory (IFN stim B Non-Switched Memory (IGH) B Non-Switched Memory (IGH) B Non-Switched Memory (IGH) B Switched FCRL3; IGHA2 B Switched Memory (IGH) B Swit				
B Naive (GHM B Non-Switched FCRL3; IGHD B Non-Switched Memory (FN stim (GHA B Non-Switched Memory (FN stim (GHA B Non-Switched Memory (GHA B Non-Switched Memory (GHA B Non-Switched Memory (GHA B Switched FCRL3; IGHA B Switched Memory (FN stim (GHA B Switched Memory (GHA B Swit				
B Non-Switched PCRL3+ (BHN B Non-Switched VERNAY B Non-Switched VERNAY B Non-Switched VERNAY B Non-Switched Memory (BH Stim B Non-Switched Memory (BH Stim B Switched VERL3+ (BHA2 B Switched FCRL3+ (BHA2 B Switched Memory (BH Stim B Switched Memory (BH Stim B Switched Memory (BH Stim (BHA1 B Switched Memory (BH Stim (BHA2 B Switched Memory (BH2 B Switched Memo				
B Non-Switched FCRL3+ (GHD B Non-Switched FCRL3+ (GHD B Non-Switched Memory (FN stim (GHA B Non-Switched Memory (FN stim (GHA B Switched FCRL3+ (GHA B Switched Memory (FN stim (GHA B Switched Memory				
B Non-Switched Memory IFN stim IGHO B Non-Switched Memory IFN stim IGHO B Non-Switched Memory IGHX B Switched CPCII.3+ IGHX B Switched Memory IFN stim IGHX B Switched Memory IGH				
B Non-Switched Memory IFN stim IGH0 B Non-Switched Memory IFN stim IGH0 B Switched FCR13+ IGH142 B Switched FCR13+ IGH62 B Switched FCR13+ IGH64 B Switched FCR13+ IGH64 B Switched Memory IFN stim IGH64 B Switched Memory IFN stim IGH65 B Switched Memory IFN stim IGH64 B Switched Memory IFN stim IGH64 B Switched Memory IFN stim IGH64 B Switched Memory IGH8 stim IGH64 B Switched Memory IGH64 B Swit		B Non–Switched FCRL3+ IGHM =		
B Non-Switched Memory (BH Minory B Switched FCRL3+ (BHA1 B Switched FCRL3+ (BHA2 B Switched FCRL3+ (BHA2 B Switched FCRL3+ (BHA2 B Switched FCRL3+ (BHA2 B Switched Memory (FN stim (BHA2 B Switched Memory (FN stim (BHA2 B Switched Memory (FN stim (BHA2 B Switched Memory		B Non–Switched Memory -		
B Non-Switched Memory IGH B Non-Switched Memory IGH B Switched FCR13+ IGHA2 B Switched Memory IFN stim IGHA2 B Switched Memory IGHA B Switched Memory IGHA B Switched Memory IGHA2 B Switc		B Non-Switched Memory IFN stim =		
B Non-Switched Memory (BHD B Non-Switched Memory (BHD B Switched FCR13+ (BHA2 B Switched Memory (FN stim (BHA1 B Switched Memory (BH stim (BHA2 B Switched Memory (BH stim (BHA2 B Switched Memory (BH stim (BHA1 B Switched Memory (BH stim (BHA1 B Switched Memory (BH stim (BHA2 B Switched Memory (BH2 B Switched Memory		B Non-Switched Memory IFN stim IGHD		
B Non-Switched Memory ICHM B Switched FCR13+ IGHA1 B Switched FCR13+ IGHA1 B Switched FCR13+ IGHA1 B Switched FCR13+ IGHA2 B Switched FCR13+ IGHA2 B Switched Memory IFN stim IGHA2 B Switched Memory IGHA B Switched M				
B Switched FCR13+ IGHA2 B Switched FCR13+ IGHA2 B Switched FCR13+ IGHA2 B Switched FCR13+ IGHA3 B Switched FCR13+ IGHA3 B Switched Memory IFN stim IGHA1 B Switched Memory IFN stim IGHA3 B Switched Memory IGHA2 B Switched Memory IGHA2 B Switched Memory IGHA3 B Switche				Expressed in
B Switched FCR13+ IGHA B Switched FCR13+ IGHA B Switched FCR13+ IGHA B Switched FCR13+ IGHA B Switched Memory IFN stim B Switched Memory IFN stim B Switched Memory IFN stim IGHA B Switched Memory IGHA B Switched Memo		B Switched FCRL3+ -		precentage
B Switched FCRL3+ IGHG B Switched FCRL3+ IGHG B Switched Memory IFN stim IGHG B Switched Memory IGHA B Switched Memory IGHA B Switched Memory IGHG B Switched Memory IGHG		B Switched FCRL3+ IGHA1 -		
B Switched PCRL3: HGHG2 B Switched PCRL3: HGHG4 B Switched Memory IFN stim IGHG2 B Switched Memory IFN stim IGHG4 B Switched Memory IFN stim IGHG4 B Switched Memory IFN stim IGHG4 B Switched Memory				
B Switched Memory IFN stim IGHA2 B Switched Memory IGHA3 B Switched Memory IGHA4 B Switched Memory IGHA44 B Switched Memory IGHA44 B Switched Memory IGHA				
B Switched Memory IRV stim B Switched Memory IRV stim B Switched Memory IRV stim IGH23 B Switched Memory IRV stim IGH24 B Switched Memory IRV stim IGH24 B Switched Memory IGH34 B Switched Memory IGH44 B Switched Memory IGH44 Plasma Cell IGH				
B Switched Memory IFN stim IGHA1 B Switched Memory IFN stim IGHA2 B Switched Memory IGHA1 B Switched Memory IGHA2 B Switched Memory IGHA2 B Switched Memory IGHA4 B Switched Memory IGHA4 Plasma Cell IGHA4 Plasma Ce		B Switched FCRL3+ IGHG3 =		
B Switched Memory IFN stim IGH62 B Switched Memory IFN stim IGH63 B Switched Memory IFN stim IGH64 B Switched Memory IGH64 Plasma Cell IGH		B Switched FCRL3+ IGRG4		
B Switched Memory IFN stim IGHA1 B Switched Memory IFN stim IGH61 B Switched Memory IFN stim IGH63 B Switched Memory IGHA2 B Switched Memory IGHA3 B S		B Switched Memory IEN stim		100
B Switched Memory IFN stim IGHA2 B Switched Memory IFN stim IGHG3 B Switched Memory IFN stim IGHG4 B Switched Memory IGHG4 Plasma Cell IGHA1 Plasma Cell IGHA1 Plasma Cell IGH64 Plasma Cell IGH		B Switched Memory IEN stim IGHA1 =		
B Switched Memory IPN stim IGH03 B Switched Memory IPN stim IGH03 B Switched Memory IGH04 B Switched Memory IGH04 Plasma Cell IGH04		B Switched Memory IEN stim IGHA2 -	· · • • • • • • • • • • • • • • • • • •	
B Switched Memory IPN stim IGHG3 B Switched Memory IPN stim IGHG4 B Switched Memory IGHG B Switched Memory IGHG B Switched Memory IGHG B Switched Memory IGHG B Switched Memory IGHG4 Plasma Cell IGHA1 Plasma Cell IGHA2 Plasma Cell IGHA2 Plasma Cell IGHG4 Plasma Cel		B Switched Memory IFN stim IGHG1 -	· • • • • • • • • • • • • • • • • • • •	
B Switched Memory IGH Stim IGHG4 B Switched Memory IGH42 B Switched Memory IGH42 B Switched Memory IGH64 B Switched Memory IGH64 Plasma Cell IGH64 Plasma Ce		B Switched Memory IFN stim IGHG2 -		
B Switched Memory IGHA1 B Switched Memory IGH61 B Switched Memory IGH63 B Switched Memory IGH64 B Switched Memory IGH64 B Switched Memory IGH64 Plasma Cell IGHA2 Plasma Cell IGHA2 Plasma Cell IGHA Plasma Cell IGH64 Plasma Cell I				
B Switched Memory IGH2 B Switched Memory IGH3 B Switched Memory IGH3 B Switched Memory IGH3 Plasma Cell IGH3				0
B Switched Memory IGHE B Switched Memory IGHC B Switched Memory IGHC3 B Switched Memory IGHC4 Plasma Cell IGHA Plasma Cell IG				
B Switched Memory IGH02 B Switched Memory IGH02 Plasma Cell IGH0 Plasma Cell IGH02 Plasma Cell IGH04 Plasma Cell IGH04 P		B Switched Memory IGHE		
B Switched Memory IGH02 B Switched Memory IGH02 Plasma Cell IGH0 Plasma Cell IGH02 Plasma Cell IGH04 Plasma Cell IGH04 P		B Switched Memory IGHG1 -	· • • • • • • • • • • • • • • • • • • •	
B Switched Wemory (GHG4 Plasma Cell IGHA1 Plasma Cell IGHA1 Plasma Cell IGHA1 Plasma Cell IGHA1 Plasma Cell IGHC4 Plasma		B Switched Memory IGHG2 -		Z-score)
D Simulation Britagina Cell Plasma Cell GH42 Plasma Cell GH42 Plasma Cell GH64 Plasma Cell				0
Plasma Cell IGH2 Plasma Cell IGH2 Plasma Cell IGH6 Plasma				2
Plasma Cell IGH2 Plasma Cell IGH2 Plasma Cell IGH6 Plasma				1
Plasma Cell IGHG Plasma Cell				
Plasma Cell IGHG Plasma Cell				- 0
Plasma Cell IGHG2 Plasma Cell IGHG4 Plasma Cell IGHG4 Plasma Cell IGHG4 Plasmablast IGH64 Plasmablast				- 1
Plasma Cell (GHG4 Plasma Cell (GHG4 Plasma Cell (GHG4 Plasmablast Plasmablast (GH42 Plasmablast (GH42 Plasmablast (GH42 Plasmablast (GH42 Plasmablast (GH42 Plasmablast (GH42 Plasmablast (GH44 Plasmablast (GH444 Plasmablast (GH444 Plas		Plasma Cell IGHG1 -		-1
Plasma Cell IGHG4 Plasma Cell IGHG4 Plasmablast IGHA2 Plasmablast IGHA2 Plasmablast IGHG4 Plasmablast		Plasma Cell IGHG2 -		
Plasma Cell IGHM Plasmablast Plasmablast Plasmablast Plasmablast Plasmablast Plasmablast Plasmablast IGHG1 Plasmablast IGHG2 Plasmablast IGHG2 Plasmablast IGHG4 Plasmablast I				
Plasmablast IGH04 Plasmablast				
Plasmablast IGHA1 Plasmablast IGHA1 Plasmablast IGHG1 Plasmablast IGHG2 Plasmablast IGHG3 Plasmablast IGHG4 Plasmablast				
Plasmablast IGH2 Plasmablast IGH2 Plasma				
Plasmablast (GHG1 Plasmablast (GHG2 Plasmablast (GHG2 Plasmablast (GHG2 Plasmablast (GHG4 Plasmablast IGHM Plasmablast IGHM Vitigo Rick Style (GGC Vitigo CGC Vitigo				
Plasmablast IGHG Plasmablast IGHG Plasmablast IGHM Plasmablast IGHM Vizion Rock Systems Upper Systems Vizion Rock Systems Vizi				
Plasmablast IGHG4 Plasmablast IGHM Plasmablast IGHM Station Statistics Stati				
L C C C C C C C C C C C C C C C C C C C				
		Plasmablast IGHM -		
			455445648846989694949466668886654455888	
			EFCORRECTED COCCC-CESOR OF	
SAF C			£' ½	Ε.
<u> </u>			L A	
			,- 0	

Extended Data Figure 4





Extended Data Figure 5



Extended Data Figure 6





102

BSB-H

10 APLH

10

10

10 -2

...1



102

10

100

10 -*

D3 APC-I

00 1


10.2


BSB-H

52.7

60.0

CD14 FITC-H





SSC-H

10

100